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Abstract
Overwhelming evidence shows the quality of reporting of randomised controlled trials (RCTs) is not optimal. Without transparent reporting,
readers cannot judge the reliability and validity of trial findings nor extract information for systematic reviews. Recent methodological analyses
indicate that inadequate reporting and design are associated with biased estimates of treatment effects. Such systematic error is seriously dam-
aging to RCTs, which are considered the gold standard for evaluating interventions because of their ability to minimise or avoid bias.
A group of scientists and editors developed the CONSORT (Consolidated Standards of Reporting Trials) statement to improve the qual-
ity of reporting of RCTs. It was first published in 1996 and updated in 2001. The statement consists of a checklist and flow diagram that
authors can use for reporting an RCT. Many leading medical journals and major international editorial groups have endorsed the CONSORT
statement. The statement facilitates critical appraisal and interpretation of RCTs.
During the 2001 CONSORT revision, it became clear that explanation and elaboration of the principles underlying the CONSORT state-
ment would help investigators and others to write or appraise trial reports. A CONSORT explanation and elaboration article was published
in 2001 alongside the 2001 version of the CONSORT statement.
After an expert meeting in January 2007, the CONSORT statement has been further revised and is published as the CONSORT 2010
Statement. This update improves the wording and clarity of the previous checklist and incorporates recommendations related to topics that
have only recently received recognition, such as selective outcome reporting bias.
This explanatory and elaboration documentdintended to enhance the use, understanding, and dissemination of the CONSORT state-
mentdhas also been extensively revised. It presents the meaning and rationale for each new and updated checklist item providing examples
of good reporting and, where possible, references to relevant empirical studies. Several examples of flow diagrams are included.
The CONSORT 2010 Statement, this revised explanatory and elaboration document, and the associated website (www.consort-statement.
org) should be helpful resources to improve reporting of randomised trials.  2010 Moher et al. Published by Elsevier Inc.
‘‘The whole of medicine depends on the transparent
reporting of clinical trials’’[1].
Well designed and properly executed randomised con-
trolled trials (RCTs) provide the most reliable evidence
on the efficacy of healthcare interventions, but trials with
inadequate methods are associated with bias, especially ex-
aggerated treatment effects [2e5]. Biased results from
poorly designed and reported trials can mislead decision
making in health care at all levels, from treatment deci-
sions for a patient to formulation of national public health
policies.
In order to encourage dissemination of the CONSORT 2010 Statement,
this article is freely accessible on bmj.com and will also be published in
the Journal of Clinical Epidemiology. The authors jointly hold the copy-
right for this article. For details on further use, see the CONSORt website
(www.consort-statement.org).
This is an open-access article distributed under the terms of the Crea-
tive Commons Attribution Non-commercial License, which permits use,
distribution, and reproduction in any medium, provided the original work
is properly cited, the use is non-commercial and is otherwise in compliance
with the license. See: http://creativecommons.org/licenses/by-nc/2.0/and
http://creativecommons.org/licenses/by-nc/2.0/legalcode.
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Critical appraisal of the quality of clinical trials is possi-
ble only if the design, conduct, and analysis of RCTs are
thoroughly and accurately described in the report. Far from
being transparent, the reporting of RCTs is often incom-
plete [6e9], compounding problems arising from poor
methodology [10e15].
1. Incomplete and inaccurate reporting
Many reviews have documented deficiencies in reports
of clinical trials. For example, information on the method
used in a trial to assign participants to comparison groups
was reported in only 21% of 519 trial reports indexed in
PubMed in 2000 [16], and only 34% of 616 reports indexed
in 2006 [17]. Similarly, only 45% of trial reports indexed in
PubMed in 2000 [16] and 53% in 2006 [17] defined a pri-
mary end point, and only 27% in 2000 and 45% in 2006 re-
ported a sample size calculation. Reporting is not only
often incomplete but also sometimes inaccurate. Of 119 re-
ports stating that all participants were included in the anal-
ysis in the groups to which they were originally assigned
(intention-to-treat analysis), 15 (13%) excluded patients
or did not analyse all patients as allocated [18]. Many other
reviews have found that inadequate reporting is common in
specialty journals [16,19] and journals published in lan-
guages other than English [20,21].
Proper randomisation reduces selection bias at trial entry
and is the crucial component of high quality RCTs [22].
Successful randomisation hinges on two steps: generation
of an unpredictable allocation sequence and concealment
of this sequence from the investigators enrolling partici-
pants (see Box 1) [2,23].
Unfortunately, despite that central role, reporting of the
methods used for allocation of participants to interventions
is also generally inadequate. For example, 5% of 206 re-
ports of supposed RCTs in obstetrics and gynaecology jour-
nals described studies that were not truly randomised [23].
This estimate is conservative, as most reports do not at
present provide adequate information about the method of
allocation [20,23,30e33].
2. Improving the reporting of RCTs: the CONSORT
statement
DerSimonian and colleagues suggested that ‘‘editors
could greatly improve the reporting of clinical trials by pro-
viding authors with a list of items that they expected to be
strictly reported’’[34]. Early in the 1990s, two groups of
journal editors, trialists, and methodologists independently
published recommendations on the reporting of trials
[35,36]. In a subsequent editorial, Rennie urged the two
groups to meet and develop a common set of recommenda-
tions [37]; the outcome was the CONSORT statement
(Consolidated Standards of Reporting Trials) [38].
The CONSORT statement (or simply CONSORT) com-
prises a checklist of essential items that should be included
in reports of RCTs and a diagram for documenting the flow
of participants through a trial. It is aimed at primary reports
of RCTs with two group, parallel designs. Most of CONSORT
is also relevant to a wider class of trial designs, such as non-
inferiority, equivalence, factorial, cluster, and crossover trials.
Extensions to the CONSORT checklist for reporting trials with
some of these designs have been published [39e41], as have
those for reporting certain types of data (harms [42]), types
of interventions (non-pharmacological treatments [43], herbal
interventions [44]), and abstracts [45].
The objective of CONSORT is to provide guidance to
authors about how to improve the reporting of their trials.
Box 1. Treatment allocation. What’s so special about randomisation?
The method used to assign interventions to trial participants is a crucial aspect of clinical trial design. Random as-
signment is the preferred method; it has been successfully used regularly in trials for more than 50 years [24].
Randomisation has three major advantages [25]. First, when properly implemented, it eliminates selection bias,
balancing both known and unknown prognostic factors, in the assignment of treatments. Without randomisation,
treatment comparisons may be prejudiced, whether consciously or not, by selection of participants of a particular
kind to receive a particular treatment. Second, random assignment permits the use of probability theory to express
the likelihood that any difference in outcome between intervention groups merely reflects chance [26]. Third,
random allocation, in some situations, facilitates blinding the identity of treatments to the investigators, participants,
and evaluators, possibly by use of a placebo, which reduces bias after assignment of treatments [27]. Of these three
advantages, reducing selection bias at trial entry is usually the most important [28].
Successful randomisation in practice depends on two interrelated aspectsdadequate generation of an unpredictable
allocation sequence and concealment of that sequence until assignment occurs [2,23]. A key issue is whether the sched-
ule is known or predictable by the people involved in allocating participants to the comparison groups [29]. The
treatment allocation system should thus be set up so that the person enrolling participants does not know in advance
which treatment the next person will get, a process termed allocation concealment [2,23]. Proper allocation conceal-
ment shields knowledge of forthcoming assignments, whereas proper random sequences prevent correct anticipation
of future assignments based on knowledge of past assignments.
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Trial reports need be clear, complete, and transparent.
Readers, peer reviewers, and editors can also use CON-
SORT to help them critically appraise and interpret reports
of RCTs. However, CONSORT was not meant to be used as
a quality assessment instrument. Rather, the content of
CONSORT focuses on items related to the internal and ex-
ternal validity of trials. Many items not explicitly men-
tioned in CONSORT should also be included in a report,
such as information about approval by an ethics committee,
obtaining informed consent from participants, and, where
relevant, existence of a data safety and monitoring commit-
tee. In addition, any other aspects of a trial that are men-
tioned should be properly reported, such as information
pertinent to cost effectiveness analysis [46e48].
Since its publication in 1996, CONSORT has been sup-
ported by more than 400 journals (www.consort-statement.
org) and several editorial groups, such as the International
Committee of Medical Journal Editors [49]. The introduc-
tion of CONSORT within journals is associated with im-
proved quality of reports of RCTs [17,50,51]. However,
CONSORT is an ongoing initiative, and the CONSORT
statement is revised periodically [3]. CONSORT was last
revised nine years ago, in 2001 [52e54]. Since then the ev-
idence base to inform CONSORT has grown considerably;
empirical data have highlighted new concerns regarding the
reporting of RCTs, such as selective outcome reporting
[55e57]. A CONSORT Group meeting was therefore con-
vened in January 2007, in Canada, to revise the 2001 CON-
SORT statement and its accompanying explanation and
elaboration document. The revised checklist is shown in
Table 1 and the flow diagram, not revised, in Fig 1 [52e54].
3. The CONSORT 2010 Statement: explanation and
elaboration
During the 2001 CONSORT revision, it became clear
that explanation and elaboration of the principles underly-
ing the CONSORT statement would help investigators
and others to write or appraise trial reports. The CONSORT
explanation and elaboration article [58] was published in
2001 alongside the 2001 version of the CONSORT state-
ment. It discussed the rationale and scientific background
for each item and provided published examples of good re-
porting. The rationale for revising that article is similar to
that for revising the statement, described above. We briefly
describe below the main additions and deletions to this ver-
sion of the explanation and elaboration article.
4. The CONSORT 2010 Explanation and Elaboration:
changes
We have made several substantive and some cosmetic
changes to this version of the CONSORT explanatory doc-
ument (full details are highlighted in the 2010 version of
the CONSORT statement [59]). Some reflect changes to
the CONSORT checklist; there are three new checklist
items in the CONSORT 2010 checklistdsuch as item 24,
which asks authors to report where their trial protocol can
be accessed. We have also updated some existing explana-
tions, including adding more recent references to methodo-
logical evidence, and used some better examples. We have
removed the glossary, which is now available on the CON-
SORT website (www.consort-statement.org). Where possi-
ble, we describe the findings of relevant empirical
studies. Many excellent books on clinical trials offer fuller
discussion of methodological issues [60e62]. Finally, for
convenience, we sometimes refer to ‘‘treatments’’ and ‘‘pa-
tients,’’ although we recognise that not all interventions
evaluated in RCTs are treatments and not all participants
are patients.
5. Checklist items
5.1. Title and abstract
5.1.1. Item 1a. Identification as a randomised trial in
the title
Exampled‘‘Smoking reduction with oral nicotine in-
halers: double blind, randomised clinical trial of efficacy
and safety’’[63].
ExplanationdThe ability to identify a report of a rando-
mised trial in an electronic database depends to a large ex-
tent on how it was indexed. Indexers may not classify
a report as a randomised trial if the authors do not explicitly
report this information [64]. To help ensure that a study is
appropriately indexed and easily identified, authors should
use the word ‘‘randomised’’ in the title to indicate that the
participants were randomly assigned to their comparison
groups.
5.1.2. Item 1b. Structured summary of trial design,
methods, results, and conclusions
For specific guidance see CONSORT for abstracts
[45,65].
ExplanationdClear, transparent, and sufficiently de-
tailed abstracts are important because readers often base
their assessment of a trial on such information. Some
readers use an abstract as a screening tool to decide whether
to read the full article. However, as not all trials are freely
available and some health professionals do not have access
to the full trial reports, healthcare decisions are sometimes
made on the basis of abstracts of randomised trials [66].
A journal abstract should contain sufficient information
about a trial to serve as an accurate record of its conduct
and findings, providing optimal information about the trial
within the space constraints and format of a journal. A
properly constructed and written abstract helps individuals
to assess quickly the relevance of the findings and aids the
retrieval of relevant reports from electronic databases [67].
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Table 1
CONSORT 2010 checklist of information to include when reporting a randomised trial*
Section/Topic Item No Checklist item Reported on page No
Title and abstract
1a Identification as a randomised trial in the title
1b Structured summary of trial design, methods, results, and conclusions
(for specific guidance see CONSORT for abstracts [45,65])
Introduction
Background and objectives 2a Scientific background and explanation of rationale
2b Specific objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) including
allocation ratio
3b Important changes to methods after trial commencement (such as
eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details to allow
replication, including how and when they were actually administered
Outcomes 6a Completely defined pre-specified primary and secondary outcome
measures, including how and when they were assessed
6b Any changes to trial outcomes after the trial commenced, with reasons
Sample size 7a How sample size was determined
7b When applicable, explanation of any interim analyses and stopping
guidelines
Randomisation:
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as blocking and
block size)
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation sequence (such as
sequentially numbered containers), describing any steps taken to
conceal the sequence until interventions were assigned
Implementation 10 Who generated the random allocation sequence, who enrolled
participants, and who assigned participants to interventions
Blinding 11a If done, who was blinded after assignment to interventions (for example,
participants, care providers, those assessing outcomes) and how
11b If relevant, description of the similarity of interventions
Statistical methods 12a Statistical methods used to compare groups for primary and secondary
outcomes
12b Methods for additional analyses, such as subgroup analyses and
adjusted analyses
Results
Participant flow (a diagram
is strongly recommended)
13a For each group, the numbers of participants who were randomly
assigned, received intended treatment, and were analysed for the
primary outcome
13b For each group, losses and exclusions after randomisation, together with
reasons
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline demographic and clinical characteristics for
each group
Numbers analysed 16 For each group, number of participants (denominator) included in each
analysis and whether the analysis was by original assigned groups
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and
the estimated effect size and its precision (such as 95% confidence
interval)
17b For binary outcomes, presentation of both absolute and relative effect
sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses
and adjusted analyses, distinguishing pre-specified from exploratory
Harms 19 All important harms or unintended effects in each group (for specific
guidance see CONSORT for harms [42])
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and,
if relevant, multiplicity of analyses
(Continued )
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The abstract should accurately reflect what is included in
the full journal article and should not include information
that does not appear in the body of the paper. Studies com-
paring the accuracy of information reported in a journal ab-
stract with that reported in the text of the full publication
have found claims that are inconsistent with, or missing
from, the body of the full article [68e71]. Conversely,
omitting important harms from the abstract could seriously
mislead someone’s interpretation of the trial findings
[42,72].
A recent extension to the CONSORT statement provides
a list of essential items that authors should include when
reporting the main results of a randomised trial in a journal
(or conference) abstract (see Table 2) [45]. We strongly
recommend the use of structured abstracts for reporting
randomised trials. They provide readers with information
about the trial under a series of headings pertaining to
the design, conduct, analysis, and interpretation [73]. Some
studies have found that structured abstracts are of higher
quality than the more traditional descriptive abstracts
[74,75] and that they allow readers to find information
more easily [76]. We recognise that many journals have de-
veloped their own structure and word limit for reporting
abstracts. It is not our intention to suggest changes to these
formats, but to recommend what information should be
reported.
5.2. Introduction
5.2.1. Item 2a. Scientific background and explanation of
rationale
Exampled‘‘Surgery is the treatment of choice for pa-
tients with disease stage I and II non-small cell lung cancer
(NSCLC) . An NSCLC meta-analysis combined the re-
sults from eight randomised trials of surgery versus surgery
plus adjuvant cisplatin-based chemotherapy and showed
a small, but not significant (p50.08), absolute survival ben-
efit of around 5% at 5 years (from 50% to 55%). At the time
the current trial was designed (mid-1990s), adjuvant
chemotherapy had not become standard clinical practice
. The clinical rationale for neo-adjuvant chemotherapy
is three-fold: regression of the primary cancer could be
achieved thereby facilitating and simplifying or reducing
subsequent surgery; undetected micro-metastases could be
dealt with at the start of treatment; and there might be in-
hibition of the putative stimulus to residual cancer by
growth factors released by surgery and by subsequent
wound healing . The current trial was therefore set up
to compare, in patients with resectable NSCLC, surgery
alone versus three cycles of platinum-based chemotherapy
followed by surgery in terms of overall survival, quality
of life, pathological staging, resectability rates, extent of
surgery, and time to and site of relapse’’[77].
ExplanationdTypically, the introduction consists of
free flowing text, in which authors explain the scientific
background and rationale for their trial, and its general out-
line. It may also be appropriate to include here the objec-
tives of the trial (see item 2b). The rationale may be
explanatory (for example, to assess the possible influence
of a drug on renal function) or pragmatic (for example,
to guide practice by comparing the benefits and harms of
two treatments). Authors should report any evidence of
the benefits and harms of active interventions included in
a trial and should suggest a plausible explanation for
how the interventions might work, if this is not obvious
[78].
The Declaration of Helsinki states that biomedical re-
search involving people should be based on a thorough
knowledge of the scientific literature [79]. That is, it is un-
ethical to expose humans unnecessarily to the risks of re-
search. Some clinical trials have been shown to have
been unnecessary because the question they addressed
had been or could have been answered by a systematic re-
view of the existing literature [80,81]. Thus, the need for
a new trial should be justified in the introduction. Ideally,
it should include a reference to a systematic review of
previous similar trials or a note of the absence of such trials
[82].
Table 1
Continued
Section/Topic Item No Checklist item Reported on page No
Generalisability 21 Generalisability (external validity, applicability) of the trial findings
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and
considering other relevant evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Funding 25 Sources of funding and other support (such as supply of drugs),
role of funders
* We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all
the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials [40], non-inferiority and equivalence trials [39], non-
pharmacological treatments [43], herbal interventions [44], and pragmatic trials [41]. Additional extensions are forthcoming: for those and for up to date
references relevant to this checklist, see www.consort-statement.org.
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5.2.2. Item 2b. Specific objectives or hypotheses
Exampled‘‘In the current study we tested the hypothe-
sis that a policy of active management of nulliparous labour
would: 1. reduce the rate of caesarean section, 2. reduce the
rate of prolonged labour; 3. not influence maternal satisfac-
tion with the birth experience’’[83].
ExplanationdObjectives are the questions that the trial
was designed to answer. They often relate to the efficacy
of a particular therapeutic or preventive intervention.
Hypotheses are pre-specified questions being tested to help
meet the objectives. Hypotheses are more specific than ob-
jectives and are amenable to explicit statistical evaluation.
In practice, objectives and hypotheses are not always easily
differentiated. Most reports of RCTs provide adequate in-
formation about trial objectives and hypotheses [84].
5.3. Methods
5.3.1. Item 3a. Description of trial design (such as
parallel, factorial) including allocation ratio
Exampled‘‘This was a multicenter, stratified (6 to 11
years and 12 to 17 years of age, with imbalanced
randomisation [2:1]), double-blind, placebo-controlled,
parallel-group study conducted in the United States (41
sites)’’[85].
ExplanationdThe word ‘‘design’’ is often used to refer
to all aspects of how a trial is set up, but it also has a nar-
rower interpretation. Many specific aspects of the broader
trial design, including details of randomisation and blind-
ing, are addressed elsewhere in the CONSORT checklist.
Here we seek information on the type of trial, such as par-
allel group or factorial, and the conceptual framework, such
as superiority or non-inferiority, and other related issues not
addressed elsewhere in the checklist.
The CONSORT statement focuses mainly on trials with
participants individually randomised to one of two ‘‘paral-
lel’’ groups. In fact, little more than half of published trials
have such a design [16]. The main alternative designs are
multi-arm parallel, crossover, cluster [40], and factorial de-
signs. Also, most trials are set to identify the superiority of
a new intervention, if it exists, but others are designed to
assess non-inferiority or equivalence [39]. It is important
that researchers clearly describe these aspects of their trial,
including the unit of randomisation (such as patient, GP
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eligibility (n = …)
Excluded (n = …)
Not meeting
inclusion criteria
(n = …) 
Declined to participate
(n = …)
Other reasons (n = …)
Randomised (n = …) 
Lost to follow up (n = …) 
(give reasons) 
Discontinued intervention 
(n = …) (give reasons)
Analysed (n = …)
Excluded from analysis
(give reasons) (n = …)
Allocated to intervention 
(n = …) 
Received allocated 
intervention  (n = …)
Did not receive allocated
intervention  
(give  reasons) (n = …)
Lost to follow up (n = …) 
(give reasons) 
Discontinued intervention 
(n = …) (give reasons)
Allocated to intervention 
(n = …)
Received allocated 
intervention  (n = …)
Did not receive allocated
intervention  
(give  reasons) (n = …)
Analysed (n = …)
Excluded from analysis
(give reasons) (n = …)
Fig. 1. Flow diagram of the progress through the phases of a parallel randomised trial of two groups (that is, enrolment, intervention allocation, follow-up,
and data analysis) [52e54].
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practice, lesion). It is desirable also to include these details
in the abstract (see item 1b).
If a less common design is employed, authors are
encouraged to explain their choice, especially as such
designs may imply the need for a larger sample size or
more complex analysis and interpretation.
Although most trials use equal randomisation (such as
1:1 for two groups), it is helpful to provide the allocation
ratio explicitly. For drug trials, specifying the phase of
the trial (I-IV) may also be relevant.
5.3.2. Item 3b. Important changes to methods after trial
commencement (such as eligibility criteria), with
reasons
Exampled‘‘Patients were randomly assigned to one of
six parallel groups, initially in 1:1:1:1:1:1 ratio, to receive
either one of five otamixaban . regimens . or an active
control of unfractionated heparin . an independent Data
Monitoring Committee reviewed unblinded data for patient
safety; no interim analyses for efficacy or futility were
done. During the trial, this committee recommended that
the group receiving the lowest dose of otamixaban (0$035
mg/kg/h) be discontinued because of clinical evidence of
inadequate anticoagulation. The protocol was immediately
amended in accordance with that recommendation, and par-
ticipants were subsequently randomly assigned in 2:2:2:2:1
ratio to the remaining otamixaban and control groups,
respectively’’[86].
ExplanationdA few trials may start without any fixed
plan (that is, are entirely exploratory), but the most will
have a protocol that specifies in great detail how the trial
will be conducted. There may be deviations from the orig-
inal protocol, as it is impossible to predict every possible
change in circumstances during the course of a trial. Some
trials will therefore have important changes to the methods
after trial commencement.
Changes could be due to external information becoming
available from other studies, or internal financial difficul-
ties, or could be due to a disappointing recruitment rate.
Such protocol changes should be made without breaking
the blinding on the accumulating data on participants’ out-
comes. In some trials, an independent data monitoring com-
mittee will have as part of its remit the possibility of
recommending protocol changes based on seeing unblinded
data. Such changes might affect the study methods (such as
changes to treatment regimens, eligibility criteria, random-
isation ratio, or duration of follow-up) or trial conduct (such
as dropping a centre with poor data quality) [87].
Some trials are set up with a formal ‘‘adaptive’’ design.
There is no universally accepted definition of these designs,
but a working definition might be ‘‘a multistage study
design that uses accumulating data to decide how to modify
aspects of the study without undermining the validity and
integrity of the trial’’[88]. The modifications are usually
to the sample sizes and the number of treatment arms and
can lead to decisions being made more quickly and with
more efficient use of resources. There are, however, impor-
tant ethical, statistical, and practical issues in considering
such a design [89,90].
Whether the modifications are explicitly part of the trial
design or in response to changing circumstances, it is essen-
tial that they are fully reported to help the reader interpret
the results. Changes from protocols are not currently well
reported. A review of comparisons with protocols showed
that about half of journal articles describing RCTs had an
unexplained discrepancy in the primary outcomes [57]. Fre-
quent unexplained discrepancies have also been observed
for details of randomisation, blinding [91], and statistical
analyses [92].
Table 2
Items to include when reporting a randomised trial in a journal abstract
Item Description
Authors Contact details for the corresponding author
Trial design Description of the trial design (such as parallel, cluster, non-inferiority)
Methods:
Participants Eligibility criteria for participants and the settings where the data were collected
Interventions Interventions intended for each group
Objective Specific objective or hypothesis
Outcome Clearly defined primary outcome for this report
Randomisation How participants were allocated to interventions
Blinding (masking) Whether participants, care givers, and those assessing the outcomes were blinded to group assignment
Results:
Numbers randomised Number of participants randomised to each group
Recruitment Trial status
Numbers analysed Number of participants analysed in each group
Outcome For the primary outcome, a result for each group and the estimated effect size and its precision
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
e7D. Moher et al. / Journal of Clinical Epidemiology 63 (2010) e1ee37
5.3.3. Item 4a. Eligibility criteria for participants
Exampled‘‘Eligible participants were all adults aged 18
or over with HIV who met the eligibility criteria for antire-
troviral therapy according to the Malawian national HIV
treatment guidelines (WHO clinical stage III or IV or any
WHO stage with a CD4 count !250/mm3) and who were
starting treatment with a BMI !18.5. Exclusion criteria
were pregnancy and lactation or participation in another
supplementary feeding programme’’[93].
ExplanationdA comprehensive description of the eligi-
bility criteria used to select the trial participants is needed
to help readers interpret the study. In particular, a clear un-
derstanding of these criteria is one of several elements
required to judge to whom the results of a trial applydthat
is, the trial’s generalisability (applicability) and relevance
to clinical or public health practice (see item 21) [94]. A
description of the method of recruitment, such as by refer-
ral or self selection (for example, through advertisements),
is also important in this context. Because they are applied
before randomisation, eligibility criteria do not affect the
internal validity of a trial, but they are central to its external
validity.
Typical and widely accepted selection criteria relate to
the nature and stage of the disease being studied, the exclu-
sion of persons thought to be particularly vulnerable to
harm from the study intervention, and to issues required
to ensure that the study satisfies legal and ethical norms.
Informed consent by study participants, for example, is typ-
ically required in intervention studies. The common dis-
tinction between inclusion and exclusion criteria is
unnecessary; the same criterion can be phrased to include
or exclude participants [95].
Despite their importance, eligibility criteria are often not
reported adequately. For example, eight published trials
leading to clinical alerts by the National Institutes of Health
specified an average of 31 eligibility criteria in their proto-
cols, but only 63% of the criteria were mentioned in the
journal articles, and only 19% were mentioned in the clin-
ical alerts [96]. Similar deficiencies were found for HIV
clinical trials [97]. Among 364 reports of RCTs in surgery,
25% did not specify any eligibility criteria [98].
5.3.4. Item 4b. Settings and locations where the data
were collected
Exampled‘‘The study took place at the antiretroviral
therapy clinic of Queen Elizabeth Central Hospital in Blan-
tyre, Malawi, from January 2006 to April 2007. Blantyre is
the major commercial city of Malawi, with a population of
1 000 000 and an estimated HIV prevalence of 27% in
adults in 2004’’[93].
ExplanationdAlong with the eligibility criteria for par-
ticipants (see item 4a) and the description of the interven-
tions (see item 5), information on the settings and
locations is crucial to judge the applicability and generalis-
ability of a trial. Were participants recruited from primary,
secondary, or tertiary health care or from the community?
Healthcare institutions vary greatly in their organisation,
experience, and resources and the baseline risk for the con-
dition under investigation. Other aspects of the setting (in-
cluding the social, economic, and cultural environment and
the climate) may also affect a study’s external validity.
Authors should report the number and type of settings
and describe the care providers involved. They should re-
port the locations in which the study was carried out,
including the country, city if applicable, and immediate en-
vironment (for example, community, office practice, hospi-
tal clinic, or inpatient unit). In particular, it should be clear
whether the trial was carried out in one or several centres
(‘‘multicentre trials’’). This description should provide
enough information so that readers can judge whether the
results of the trial could be relevant to their own setting.
The environment in which the trial is conducted may differ
considerably from the setting in which the trial’s results are
later used to guide practice and policy [94,99]. Authors
should also report any other information about the settings
and locations that could have influenced the observed re-
sults, such as problems with transportation that might have
affected patient participation or delays in administering
interventions.
5.3.5. Item 5. The interventions for each group with suf-
ficient details to allow replication, including how and
when they were actually administered
Examplesd‘‘In POISE, patients received the first dose
of the study drug (ie, oral extended-release metoprolol
100 mg or matching placebo) 2e4 h before surgery. Study
drug administration required a heart rate of 50 bpm or more
and a systolic blood pressure of 100 mm Hg or greater;
these haemodynamics were checked before each adminis-
tration. If, at any time during the first 6 h after surgery,
heart rate was 80 bpm or more and systolic blood pressure
was 100 mm Hg or higher, patients received their first post-
operative dose (extended-release metoprolol 100 mg or
matched placebo) orally. If the study drug was not given
during the first 6 h, patients received their first postopera-
tive dose at 6 h after surgery. 12 h after the first postoper-
ative dose, patients started taking oral extended-release
metoprolol 200 mg or placebo every day for 30 days. If
a patient’s heart rate was consistently below 45 bpm or their
systolic blood pressure dropped below 100 mm Hg, study
drug was withheld until their heart rate or systolic blood
pressure recovered; the study drug was then restarted at
100 mg once daily. Patients whose heart rate was consis-
tently 45e49 bpm and systolic blood pressure exceeded
100 mm Hg delayed taking the study drug for 12 h’’[100].
‘‘Patients were randomly assigned to receive a custom-
made neoprene splint to be worn at night or to usual care.
The splint was a rigid rest orthosis recommended for use
only at night. It covered the base of the thumb and the the-
nar eminence but not the wrist (Figure 1). Splints were
made by 3 trained occupational therapists, who adjusted
the splint for each patient so that the first web could be
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opened and the thumb placed in opposition with the first
long finger. Patients were encouraged to contact the occu-
pational therapist if they felt that the splint needed adjust-
ment, pain increased while wearing the splint, or they had
adverse effects (such as skin erosion). Because no treatment
can be considered the gold standard in this situation,
patients in the control and intervention groups received
usual care at the discretion of their physician (general
practitioner or rheumatologist). We decided not to use
a placebo because, to our knowledge, no placebo for
splinting has achieved successful blinding of patients, as
recommended’’[101].
ExplanationdAuthors should describe each intervention
thoroughly, including control interventions. The description
should allow a clinician wanting to use the intervention to
know exactly how to administer the intervention that was
evaluated in the trial [102]. For a drug intervention, infor-
mation would include the drug name, dose, method of
administration (such as oral, intravenous), timing and dura-
tion of administration, conditions under which interven-
tions are withheld, and titration regimen if applicable. If
the control group is to receive ‘‘usual care’’ it is important
to describe thoroughly what that constitutes. If the control
group or intervention group is to receive a combination
of interventions the authors should provide a thorough
description of each intervention, an explanation of the order
in which the combination of interventions are introduced or
withdrawn, and the triggers for their introduction if
applicable.
Specific extensions of the CONSORT statement address
the reporting of non-pharmacologic and herbal interven-
tions and their particular reporting requirements (such as
expertise, details of how the interventions were standar-
dised) [43,44]. We recommend readers consult the
statements for non-pharmacologic and herbal interventions
as appropriate.
5.3.6. Item 6a. Completely defined pre-specified
primary and secondary outcome measures, including
how and when they were assessed
Exampled‘‘The primary endpoint with respect to effi-
cacy in psoriasis was the proportion of patients achieving
a 75% improvement in psoriasis activity from baseline to
12 weeks as measured by the PASI [psoriasis area and
severity index] Additional analyses were done on the per-
centage change in PASI scores and improvement in target
psoriasis lesions’’[103].
ExplanationdAll RCTs assess response variables, or
outcomes (end points), for which the groups are compared.
Most trials have several outcomes, some of which are of
more interest than others. The primary outcome measure
is the pre-specified outcome considered to be of greatest
importance to relevant stakeholders (such a patients, policy
makers, clinicians, funders) and is usually the one used in
the sample size calculation (see item 7). Some trials may
have more than one primary outcome. Having several
primary outcomes, however, incurs the problems of inter-
pretation associated with multiplicity of analyses (see
items 18 and 20) and is not recommended. Primary out-
comes should be explicitly indicated as such in the report
of an RCT. Other outcomes of interest are secondary out-
comes (additional outcomes). There may be several second-
ary outcomes, which often include unanticipated or
unintended effects of the intervention (see item 19), al-
though harms should always be viewed as important
whether they are labelled primary or secondary.
All outcome measures, whether primary or secondary,
should be identified and completely defined. The principle
here is that the information provided should be sufficient to
allow others to use the same outcomes [102]. When out-
comes are assessed at several time points after randomisa-
tion, authors should also indicate the pre-specified time
point of primary interest. For many non-pharmacological
interventions it is helpful to specify who assessed outcomes
(for example, if special skills are required to do so) and how
many assessors there were [43].
Where available and appropriate, the use of previously
developed and validated scales or consensus guidelines
should be reported [104,105], both to enhance quality of
measurement and to assist in comparison with similar stud-
ies [106]. For example, assessment of quality of life is
likely to be improved by using a validated instrument
[107]. Authors should indicate the provenance and proper-
ties of scales.
More than 70 outcomes were used in 196 RCTs of non-
steroidal anti-inflammatory drugs for rheumatoid arthritis
[108], and 640 different instruments had been used in
2000 trials in schizophrenia, of which 369 had been used
only once [33]. Investigation of 149 of those 2000 trials
showed that unpublished scales were a source of bias. In
non-pharmacological trials, a third of the claims of treat-
ment superiority based on unpublished scales would not
have been made if a published scale had been used [109].
Similar data have been reported elsewhere [110,111]. Only
45% of a cohort of 519 RCTs published in 2000 specified
the primary outcome [16]; this compares with 53% for
a similar cohort of 614 RCTs published in 2006 [17].
5.3.7. Item 6b. Any changes to trial outcomes after the
trial commenced, with reasons
Exampled‘‘The original primary endpoint was all-
cause mortality, but, during a masked analysis, the data
and safety monitoring board noted that overall mortality
was lower than had been predicted and that the study could
not be completed with the sample size and power originally
planned. The steering committee therefore decided to adopt
co-primary endpoints of all-cause mortality (the original
primary endpoint), together with all-cause mortality or car-
diovascular hospital admissions (the first prespecified sec-
ondary endpoint)’’[112].
ExplanationdThere are many reasons for departures
from the initial study protocol (see item 24). Authors
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should report all major changes to the protocol, including
unplanned changes to eligibility criteria, interventions, ex-
aminations, data collection, methods of analysis, and out-
comes. Such information is not always reported.
As indicated earlier (see item 6a), most trials record
multiple outcomes, with the risk that results will be
reported for only a selected subset (see item 17). Pre-
specification and reporting of primary and secondary
outcomes (see item 6a) should remove such a risk. In some
trials, however, circumstances require a change in the way
an outcome is assessed or even, as in the example above,
a switch to a different outcome. For example, there may
be external evidence from other trials or systematic reviews
suggesting the end point might not be appropriate, or
recruitment or the overall event rate in the trial may be
lower than expected [112]. Changing an end point based
on unblinded data is much more problematic, although it
may be specified in the context of an adaptive trial design
[88]. Authors should identify and explain any such changes.
Likewise, any changes after the trial began of the designa-
tion of outcomes as primary or secondary should be re-
ported and explained.
A comparison of protocols and publications of 102
randomised trials found that 62% of trials reports had at
least one primary outcome that was changed, introduced,
or omitted compared with the protocol [55]. Primary
outcomes also differed between protocols and publications
for 40% of a cohort of 48 trials funded by the Canadian
Institutes of Health Research [113]. Not one of the
subsequent 150 trial reports mentioned, let alone ex-
plained, changes from the protocol. Similar results from
other studies have been reported recently in a systematic
review of empirical studies examining outcome reporting
bias [57].
5.3.8. Item 7a. How sample size was determined
Examplesd‘‘To detect a reduction in PHS (postopera-
tive hospital stay) of 3 days (SD 5 days), which is in agree-
ment with the study of Lobo et al [17] with a two-sided 5%
significance level and a power of 80%, a sample size of 50
patients per group was necessary, given an anticipated
dropout rate of 10%. To recruit this number of patients
a 12-month inclusion period was anticipated’’[114].
‘‘Based on an expected incidence of the primary com-
posite endpoint of 11% at 2.25 years in the placebo group,
we calculated that we would need 950 primary endpoint
events and a sample size of 9650 patients to give 90%
power to detect a significant difference between ivabradine
and placebo, corresponding to a 19% reduction of relative
risk (with a two-sided type 1 error of 5%). We initially de-
signed an event-driven trial, and planned to stop when 950
primary endpoint events had occurred. However, the inci-
dence of the primary endpoint was higher than predicted,
perhaps because of baseline characteristics of the recruited
patients, who had higher risk than expected (e.g., lower pro-
portion of NYHA class I and higher rates of diabetes and
hypertension). We calculated that when 950 primary end-
point events had occurred, the most recently included pa-
tients would only have been treated for about 3 months.
Therefore, in January 2007, the executive committee de-
cided to change the study from being event-driven to
time-driven, and to continue the study until the patients
who were randomised last had been followed up for 12
months. This change did not alter the planned study dura-
tion of 3 years’’[115].
ExplanationdFor scientific and ethical reasons, the
sample size for a trial needs to be planned carefully, with
a balance between medical and statistical considerations.
Ideally, a study should be large enough to have a high prob-
ability (power) of detecting as statistically significant a clin-
ically important difference of a given size if such
a difference exists. The size of effect deemed important is
inversely related to the sample size necessary to detect it;
that is, large samples are necessary to detect small differ-
ences. Elements of the sample size calculation are (1) the
estimated outcomes in each group (which implies the clin-
ically important target difference between the intervention
groups); (2) the a (type I) error level; (3) the statistical
power (or the b (type II) error level); and (4), for continu-
ous outcomes, the standard deviation of the measurements
[116]. The interplay of these elements and their reporting
will differ for cluster trials [40] and non-inferiority and
equivalence trials [39].
Authors should indicate how the sample size was deter-
mined. If a formal power calculation was used, the authors
should identify the primary outcome on which the calcula-
tion was based (see item 6a), all the quantities used in the
calculation, and the resulting target sample size per study
group. It is preferable to quote the expected result in the
control group and the difference between the groups one
would not like to overlook. Alternatively, authors could
present the percentage with the event or mean for each
group used in their calculations. Details should be given
of any allowance made for attrition or non-compliance dur-
ing the study.
Some methodologists have written that so called under-
powered trials may be acceptable because they could ulti-
mately be combined in a systematic review and meta-
analysis [117e119], and because some information is bet-
ter than no information. Of note, important caveats ap-
plydsuch as the trial should be unbiased, reported
properly, and published irrespective of the results, thereby
becoming available for meta-analysis [118]. On the other
hand, many medical researchers worry that underpowered
trials with indeterminate results will remain unpublished
and insist that all trials should individually have ‘‘sufficient
power.’’ This debate will continue, and members of the
CONSORT Group have varying views. Critically however,
the debate and those views are immaterial to reporting
a trial. Whatever the power of a trial, authors need to prop-
erly report their intended size with all their methods and as-
sumptions [118]. That transparently reveals the power of
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the trial to readers and gives them a measure by which to
assess whether the trial attained its planned size.
In some trials, interim analyses are used to help decide
whether to stop early or to continue recruiting sometimes
beyond the planned trial end (see item 7b). If the actual
sample size differed from the originally intended sample
size for some other reason (for example, because of poor
recruitment or revision of the target sample size), the expla-
nation should be given.
Reports of studies with small samples frequently include
the erroneous conclusion that the intervention groups do
not differ, when in fact too few patients were studied to
make such a claim [120]. Reviews of published trials have
consistently found that a high proportion of trials have low
power to detect clinically meaningful treatment effects
[121e123]. In reality, small but clinically meaningful true
differences are much more likely than large differences to
exist, but large trials are required to detect them [124].
In general, the reported sample sizes in trials seem
small. The median sample size was 54 patients in 196 trials
in arthritis [108], 46 patients in 73 trials in dermatology [8],
and 65 patients in 2000 trials in schizophrenia [33]. These
small sample sizes are consistent with those of a study of
519 trials indexed in PubMed in December 2000 [16] and
a similar cohort of trials (n5616) indexed in PubMed in
2006 [17], where the median number of patients recruited
for parallel group trials was 80 across both years. More-
over, many reviews have found that few authors report
how they determined the sample size [8,14,32,33,123].
There is little merit in a post hoc calculation of statistical
power using the results of a trial; the power is then appro-
priately indicated by confidence intervals (see item 17)
[125].
5.3.9. Item 7b. When applicable, explanation of any
interim analyses and stopping guidelines
Examplesd‘‘Two interim analyses were performed dur-
ing the trial. The levels of significance maintained an over-
all P value of 0.05 and were calculated according to the
O’Brien-Fleming stopping boundaries. This final analysis
used a Z score of 1.985 with an associated P value of
0.0471’’[126].
‘‘An independent data and safety monitoring board peri-
odically reviewed the efficacy and safety data. Stopping
rules were based on modified Haybittle-Peto boundaries
of 4 SD in the first half of the study and 3 SD in the second
half for efficacy data, and 3 SD in the first half of the study
and 2 SD in the second half for safety data. Two formal in-
terim analyses of efficacy were performed when 50% and
75% of the expected number of primary events had ac-
crued; no correction of the reported P value for these in-
terim tests was performed’’[127].
ExplanationdMany trials recruit participants over a long
period. If an intervention is working particularly well or
badly, the study may need to be ended early for ethical rea-
sons. This concern can be addressed by examining results
as the data accumulate, preferably by an independent data
monitoring committee. However, performing multiple sta-
tistical examinations of accumulating data without appro-
priate correction can lead to erroneous results and
interpretations [128]. If the accumulating data from a trial
are examined at five interim analyses that use a P value
of 0.05, the overall false positive rate is nearer to 19% than
to the nominal 5%.
Several group sequential statistical methods are avail-
able to adjust for multiple analyses [129e131], and their
use should be pre-specified in the trial protocol. With these
methods, data are compared at each interim analysis, and
a P value less than the critical value specified by the group
sequential method indicates statistical significance. Some
trialists use group sequential methods as an aid to decision
making [132], whereas others treat them as a formal stop-
ping rule (with the intention that the trial will cease if the
observed P value is smaller than the critical value).
Authors should report whether they or a data monitoring
committee took multiple ‘‘looks’’ at the data and, if so, how
many there were, what triggered them, the statistical
methods used (including any formal stopping rule), and
whether they were planned before the start of the trial, be-
fore the data monitoring committee saw any interim data by
allocation, or some time thereafter. This information is
often not included in published trial reports [133], even in
trials that report stopping earlier than planned [134].
5.3.10. Item 8a. Method used to generate the random
allocation sequence
Examplesd‘‘Independent pharmacists dispensed either
active or placebo inhalers according to a computer gener-
ated randomisation list’’[63].
‘‘For allocation of the participants, a computer-
generated list of random numbers was used’’[135].
ExplanationdParticipants should be assigned to com-
parison groups in the trial on the basis of a chance (random)
process characterised by unpredictability (see Box 1).
Authors should provide sufficient information that the
reader can assess the methods used to generate the random
allocation sequence and the likelihood of bias in group
assignment. It is important that information on the process
of randomisation is included in the body of the main article
and not as a separate supplementary file; where it can be
missed by the reader.
The term ‘‘random’’ has a precise technical meaning.
With random allocation, each participant has a known prob-
ability of receiving each intervention before one is
assigned, but the assigned intervention is determined by
a chance process and cannot be predicted. However, ‘‘ran-
dom’’ is often used inappropriately in the literature to de-
scribe trials in which non-random, deterministic
allocation methods were used, such as alternation, hospital
numbers, or date of birth. When investigators use such non-
random methods, they should describe them precisely and
should not use the term ‘‘random’’ or any variation of it.
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Even the term ‘‘quasi-random’’ is unacceptable for describ-
ing such trials. Trials based on non-random methods gener-
ally yield biased results [2e4,136] Bias presumably arises
from the inability to conceal these allocation systems
adequately (see item 9).
Many methods of sequence generation are adequate.
However, readers cannot judge adequacy from such terms
as ‘‘random allocation,’’ ‘‘randomisation,’’ or ‘‘random’’
without further elaboration. Authors should specify the
method of sequence generation, such as a random-number
table or a computerised random number generator. The
sequence may be generated by the process of minimisation,
a non-random but generally acceptable method (see Box 2).
In some trials, participants are intentionally allocated in
unequal numbers to each intervention: for example, to gain
more experience with a new procedure or to limit costs of
the trial. In such cases, authors should report the random-
isation ratio (for example, 2:1 or two treatment participants
per each control participant) (see item 3a).
In a representative sample of PubMed indexed trials in
2000, only 21% reported an adequate approach to random
sequence generation [16]; this increased to 34% for a simi-
lar cohort of PubMed indexed trials in 2006 [17]. In more
than 90% of these cases, researchers used a random number
generator on a computer or a random number table.
5.3.11. Item 8b. Type of randomisation; details of any
restriction (such as blocking and block size)
Examplesd‘‘Randomization sequence was created
using Stata 9.0 (StataCorp, College Station, TX) statistical
software and was stratified by center with a 1:1 allocation
using random block sizes of 2, 4, and 6’’[137].
‘‘Participants were randomly assigned following simple
randomization procedures (computerized random numbers)
to 1 of 2 treatment groups’’[138].
ExplanationdIn trials of several hundred participants or
more simple randomisation can usually be trusted to gener-
ate similar numbers in the two trial groups [139] and to
generate groups that are roughly comparable in terms of
known and unknown prognostic variables [140]. For small-
er trials (see item 7a)dand even for trials that are not
intended to be small, as they may stop before reaching their
target sizedsome restricted randomisation (procedures to
help achieve balance between groups in size or characteris-
tics) may be useful (see Box 2).
It is important to indicate whether no restriction was
used, by stating such or by stating that ‘‘simple randomisa-
tion’’ was done. Otherwise, the methods used to restrict the
randomisation, along with the method used for random se-
lection, should be specified. For block randomisation, au-
thors should provide details on how the blocks were
generated (for example, by using a permuted block design
with a computer random number generator), the block size
or sizes, and whether the block size was fixed or randomly
varied. If the trialists became aware of the block size(s),
that information should also be reported as such knowledge
could lead to code breaking. Authors should specify
whether stratification was used, and if so, which factors
were involved (such as recruitment site, sex, disease stage),
the categorisation cut-off values within strata, and the
method used for restriction. Although stratification is a use-
ful technique, especially for smaller trials, it is complicated
to implement and may be impossible if many stratifying
factors are used. If minimisation (see Box 2) was used, it
should be explicitly identified, as should the variables in-
corporated into the scheme. If used, a random element
should be indicated.
Only 9% of 206 reports of trials in specialty journals
[23] and 39% of 80 trials in general medical journals
reported use of stratification [32]. In each case, only about
half of the reports mentioned the use of restricted random-
isation. However, these studies and that of Adetugbo and
Williams [8] found that the sizes of the treatment groups
in many trials were the same or quite similar, yet blocking
or stratification had not been mentioned. One possible
explanation for the close balance in numbers is underre-
porting of the use of restricted randomisation.
5.3.12. Item 9. Mechanism used to implement the ran-
dom allocation sequence (such as sequentially numbered
containers), describing any steps taken to conceal the
sequence until interventions were assigned
Examplesd‘‘The doxycycline and placebo were in cap-
sule form and identical in appearance. They were pre-
packed in bottles and consecutively numbered for each
woman according to the randomisation schedule. Each
woman was assigned an order number and received the cap-
sules in the corresponding prepacked bottle’’[146].
‘‘The allocation sequence was concealed from the
researcher (JR) enrolling and assessing participants in
sequentially numbered, opaque, sealed and stapled enve-
lopes. Aluminium foil inside the envelope was used to ren-
der the envelope impermeable to intense light. To prevent
subversion of the allocation sequence, the name and date
of birth of the participant was written on the envelope
and a video tape made of the sealed envelope with partici-
pant details visible. Carbon paper inside the envelope trans-
ferred the information onto the allocation card inside the
envelope and a second researcher (CC) later viewed video
tapes to ensure envelopes were still sealed when partici-
pants’ names were written on them. Corresponding enve-
lopes were opened only after the enrolled participants
completed all baseline assessments and it was time to allo-
cate the intervention’’[147].
ExplanationdItem 8a discussed generation of an unpre-
dictable sequence of assignments. Of considerable impor-
tance is how this sequence is applied when participants
are enrolled into the trial (see Box 1). A generated
allocation schedule should be implemented by using alloca-
tion concealment [23], a critical mechanism that prevents
foreknowledge of treatment assignment and thus shields
those who enroll participants from being influenced by this
e12 D. Moher et al. / Journal of Clinical Epidemiology 63 (2010) e1ee37
knowledge. The decision to accept or reject a participant
should be made, and informed consent should be obtained
from the participant, in ignorance of the next assignment in
the sequence [148].
The allocation concealment should not be confused with
blinding (see item 11). Allocation concealment seeks to
prevent selection bias, protects the assignment sequence
until allocation, and can always be successfully imple-
mented [2]. In contrast, blinding seeks to prevent perfor-
mance and ascertainment bias, protects the sequence after
allocation, and cannot always be implemented [23]. With-
out adequate allocation concealment, however, even ran-
dom, unpredictable assignment sequences can be
subverted [2,149].
Centralised or ‘‘third-party’’ assignment is especially
desirable. Many good allocation concealment mechanisms
incorporate external involvement. Use of a pharmacy or
central telephone randomisation system are two common
techniques. Automated assignment systems are likely to be-
come more common [150]. When external involvement is
not feasible, an excellent method of allocation concealment
is the use of numbered containers. The interventions (often
drugs) are sealed in sequentially numbered identical con-
tainers according to the allocation sequence [151]. Enclos-
ing assignments in sequentially numbered, opaque, sealed
envelopes can be a good allocation concealment mecha-
nism if it is developed and monitored diligently. This
method can be corrupted, however, particularly if it is
poorly executed. Investigators should ensure that the enve-
lopes are opaque when held to the light, and opened se-
quentially and only after the participant’s name and other
details are written on the appropriate envelope [143].
A number of methodological studies provide empirical
evidence to support these precautions [152,153]. Trials in
Box 2. Randomisation and minimisation
Simple randomisationdPure randomisation based on a single allocation ratio is known as simple randomisation.
Simple randomisation with a 1:1 allocation ratio is analogous to a coin toss, although we do not advocate coin tossing
for randomisation in an RCT. ‘‘Simple’’ is somewhat of a misnomer. While other randomisation schemes sound com-
plex and more sophisticated, in reality, simple randomisation is elegantly sophisticated in that it is more unpredictable
and surpasses the bias prevention levels of all other alternatives.
Restricted randomisationdAny randomised approach that is not simple randomisation. Blocked randomisation is the
most common form. Other means of restricted randomisation include replacement, biased coin, and urn randomisation,
although these are used much less frequently [141].
Blocked randomisationdBlocking is used to ensure that comparison groups will be generated according to a prede-
termined ratio, usually 1:1 or groups of approximately the same size. Blocking can be used to ensure close balance of
the numbers in each group at any time during the trial. For every block of eight participants, for example, four would be
allocated to each arm of the trial [142]. Improved balance comes at the cost of reducing the unpredictability of the
sequence. Although the order of interventions varies randomly within each block, a person running the trial could
deduce some of the next treatment allocations if he or she knew the block size [143]. Blinding the interventions,
using larger block sizes, and randomly varying the block size can ameliorate this problem.
Stratified randomisationdStratification is used to ensure good balance of participant characteristics in each group.
By chance, particularly in small trials, study groups may not be well matched for baseline characteristics, such as age
and stage of disease. This weakens the trial’s credibility [144]. Such imbalances can be avoided without sacrificing the
advantages of randomisation. Stratification ensures that the numbers of participants receiving each intervention are
closely balanced within each stratum. Stratified randomisation is achieved by performing a separate randomisation
procedure within each of two or more subsets of participants (for example, those defining each study centre, age, or
disease severity). Stratification by centre is common in multicentre trials. Stratification requires some form of
restriction (such as blocking within strata). Stratification without blocking is ineffective.
MinimisationdMinimisation ensures balance between intervention groups for several selected patient factors (such
as age) [22,60]. The first patient is truly randomly allocated; for each subsequent participant, the treatment allocation
that minimises the imbalance on the selected factors between groups at that time is identified. That allocation may then
be used, or a choice may be made at random with a heavy weighting in favour of the intervention that would minimise
imbalance (for example, with a probability of 0.8). The use of a random component is generally preferable. Minimi-
sation has the advantage of making small groups closely similar in terms of participant characteristics at all stages of
the trial. Minimisation offers the only acceptable alternative to randomisation, and some have argued that it is superior
[145]. On the other hand, minimisation lacks the theoretical basis for eliminating bias on all known and unknown
factors. Nevertheless, in general, trials that use minimisation are considered methodologically equivalent to
randomised trials, even when a random element is not incorporated.
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which the allocation sequence had been inadequately or un-
clearly concealed yielded larger estimates of treatment ef-
fects than did trials in which authors reported adequate
allocation concealment. These findings provide strong
empirical evidence that inadequate allocation concealment
contributes to bias in estimating treatment effects.
Despite the importance of the mechanism of allocation
concealment, published reports often omit such details.
The mechanism used to allocate interventions was omitted
in reports of 89% of trials in rheumatoid arthritis [108],
48% of trials in obstetrics and gynaecology journals [23],
and 44% of trials in general medical journals [32]. In a more
broadly representative sample of all randomised trials
indexed on PubMed, only 18% reported any allocation con-
cealment mechanism, but some of those reported mecha-
nisms were inadequate [16].
5.3.13. Item 10. Who generated the allocation sequence,
who enrolled participants, and who assigned partici-
pants to interventions
Examplesd‘‘Determination of whether a patient would
be treated by streptomycin and bed-rest (S case) or by bed-
rest alone (C case) was made by reference to a statistical
series based on random sampling numbers drawn up for
each sex at each centre by Professor Bradford Hill; the de-
tails of the series were unknown to any of the investigators
or to the co-ordinator . After acceptance of a patient by
the panel, and before admission to the streptomycin centre,
the appropriate numbered envelope was opened at the cen-
tral office; the card inside told if the patient was to be an S
or a C case, and this information was then given to the med-
ical officer of the centre’’[24].
‘‘Details of the allocated group were given on coloured
cards contained in sequentially numbered, opaque, sealed
envelopes. These were prepared at the NPEU and kept in
an agreed location on each ward. Randomisation took place
at the end of the 2nd stage of labour when the midwife con-
sidered a vaginal birth was imminent. To enter a women
into the study, the midwife opened the next consecutively
numbered envelope’’[154].
‘‘Block randomisation was by a computer generated ran-
dom number list prepared by an investigator with no clini-
cal involvement in the trial. We stratified by admission for
an oncology related procedure. After the research nurse had
obtained the patient’s consent, she telephoned a contact
who was independent of the recruitment process for alloca-
tion consignment’’[155].
ExplanationdAs noted in item 9, concealment of the al-
located intervention at the time of enrolment is especially
important. Thus, in addition to knowing the methods used,
it is also important to understand how the random sequence
was implementeddspecifically, who generated the alloca-
tion sequence, who enrolled participants, and who assigned
participants to trial groups.
The process of randomising participants into a trial has
three different steps: sequence generation, allocation
concealment, and implementation (see Box 3). Although
the same people may carry out more than one process under
each heading, investigators should strive for complete
separation of the people involved with generation and
allocation concealment from the people involved in the im-
plementation of assignments. Thus, if someone is involved
in the sequence generation or allocation concealment steps,
ideally they should not be involved in the implementation
step.
Even with flawless sequence generation and allocation
concealment, failure to separate creation and concealment
of the allocation sequence from assignment to study group
may introduce bias. For example, the person who generated
an allocation sequence could retain a copy and consult it
when interviewing potential participants for a trial. Thus,
that person could bias the enrolment or assignment process,
regardless of the unpredictability of the assignment se-
quence. Investigators must then ensure that the assignment
schedule is unpredictable and locked away (such as in a safe
deposit box in a building rather inaccessible to the enrol-
ment location) from even the person who generated it.
The report of the trial should specify where the investiga-
tors stored the allocation list.
5.3.14. Item 11a. If done, who was blinded after assign-
ment to interventions (for example, participants, care
providers, those assessing outcomes) and how
Examplesd‘‘Whereas patients and physicians allocated
to the intervention group were aware of the allocated arm,
outcome assessors and data analysts were kept blinded to
the allocation’’[156].
‘‘Blinding and equipoise were strictly maintained by
emphasising to intervention staff and participants that each
diet adheres to healthy principles, and each is advocated by
certain experts to be superior for long-term weight-loss. Ex-
cept for the interventionists (dieticians and behavioural
psychologists), investigators and staff were kept blind to
diet assignment of the participants. The trial adhered to es-
tablished procedures to maintain separation between staff
that take outcome measurements and staff that deliver the
intervention. Staff members who obtained outcome mea-
surements were not informed of the diet group assignment.
Intervention staff, dieticians and behavioural psychologists
who delivered the intervention did not take outcome mea-
surements. All investigators, staff, and participants were
kept masked to outcome measurements and trial
results’’[157].
ExplanationdThe term ‘‘blinding’’ or ‘‘masking’’ refers
to withholding information about the assigned interventions
from people involved in the trial who may potentially be
influenced by this knowledge. Blinding is an important
safeguard against bias, particularly when assessing subjec-
tive outcomes [153].
Benjamin Franklin has been credited as being the first to
use blinding in a scientific experiment [158]. He blind-
folded participants so they would not know when he was
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applying mesmerism (a popular ‘‘healing fluid’’ of the 18th
century) and in so doing showed that mesmerism was
a sham. Based on this experiment, the scientific community
recognised the power of blinding to reduce bias, and it has
remained a commonly used strategy in scientific
experiments.
Box 4, on blinding terminology, defines the groups of
individuals (that is, participants, healthcare providers,
data collectors, outcome adjudicators, and data analysts)
who can potentially introduce bias into a trial through
knowledge of the treatment assignments. Participants
may respond differently if they are aware of their treat-
ment assignment (such as responding more favourably
when they receive the new treatment) [153]. Lack of
blinding may also influence compliance with the inter-
vention, use of co-interventions, and risk of dropping
out of the trial.
Unblinded healthcare providers may introduce similar
biases, and unblinded data collectors may differentially
assess outcomes (such as frequency or timing), repeat mea-
surements of abnormal findings, or provide encouragement
during performance testing. Unblinded outcome adjudica-
tors may differentially assess subjective outcomes, and
unblinded data analysts may introduce bias through the
choice of analytical strategies, such as the selection of
favourable time points or outcomes, and by decisions to
remove patients from the analyses. These biases have been
well documented [71,153,159e162].
Blinding, unlike allocation concealment (see item 10),
may not always be appropriate or possible. An example is
a trial comparing levels of pain associated with sampling
blood from the ear or thumb [163]. Blinding is particularly
important when outcome measures involve some subjectiv-
ity, such as assessment of pain. Blinding of data collectors
and outcome adjudicators is unlikely to matter for objective
outcomes, such as death from any cause. Even then, how-
ever, lack of participant or healthcare provider blinding
can lead to other problems, such as differential attrition
[164]. In certain trials, especially surgical trials, blinding
of participants and surgeons is often difficult or impossible,
but blinding of data collectors and outcome adjudicators is
often achievable. For example, lesions can be photographed
before and after treatment and assessed by an external ob-
server [165]. Regardless of whether blinding is possible,
authors can and should always state who was blinded (that
is, participants, healthcare providers, data collectors, and
outcome adjudicators).
Unfortunately, authors often do not report whether blind-
ing was used [166]. For example, reports of 51% of 506 tri-
als in cystic fibrosis [167], 33% of 196 trials in rheumatoid
arthritis [108], and 38% of 68 trials in dermatology [8] did
not state whether blinding was used. Until authors of trials
improve their reporting of blinding, readers will have diffi-
culty in judging the validity of the trials that they may wish
to use to guide their clinical practice.
The term masking is sometimes used in preference to
blinding to avoid confusion with the medical condition of
being without sight. However, ‘‘blinding’’ in its methodo-
logical sense seems to be understood worldwide and is
acceptable for reporting clinical trials [165,168]
Box 3. Steps in a typical randomisation process
Sequence generation
 Generate allocation sequence by some random procedure
Allocation concealment
 Develop allocation concealment mechanism (such as numbered, identical bottles or sequentially numbered, sealed,
opaque envelopes)
 Prepare the allocation concealment mechanism using the allocation sequence from the sequence generation step
Implementation
 Enrol participants:
Assess eligibility
Discuss the trial
Obtain informed consent
Enrol participant in trial
 Ascertain intervention assignment (such as opening next envelope)
 Administer intervention
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5.3.15. Item 11b. If relevant, description of the
similarity of interventions
Exampled‘‘Jamieson Laboratories Inc provided 500-
mg immediate release niacin in a white, oblong, bisect cap-
let. We independently confirmed caplet content using high
performance liquid chromatography . The placebo was
matched to the study drug for taste, color, and size, and
contained microcrystalline cellulose, silicon dioxide, dical-
cium phosphate, magnesium stearate, and stearic
acid’’[172].
ExplanationdJust as we seek evidence of concealment
to assure us that assignment was truly random, we seek ev-
idence of the method of blinding. In trials with blinding of
participants or healthcare providers, authors should state
the similarity of the characteristics of the interventions
(such as appearance, taste, smell, and method of adminis-
tration) [35,173]
Some people have advocated testing for blinding by
asking participants or healthcare providers at the end of
a trial whether they think the participant received the ex-
perimental or control intervention [174]. Because partici-
pants and healthcare providers will usually know
whether the participant has experienced the primary out-
come, this makes it difficult to determine if their responses
reflect failure of blinding or accurate assumptions about
the efficacy of the intervention [175]. Given the uncer-
tainty this type of information provides, we have removed
advocating reporting this type of testing for blinding from
the CONSORT 2010 Statement. We do, however, advocate
that the authors report any known compromises in blind-
ing. For example, authors should report if it was necessary
to unblind any participants at any point during the conduct
of a trial.
5.3.16. Item 12a. Statistical methods used to compare
groups for primary and secondary outcomes
Exampled‘‘The primary endpoint was change in body-
weight during the 20 weeks of the study in the intention-to-
treat population . Secondary efficacy endpoints included
change in waist circumference, systolic and diastolic blood
pressure, prevalence of metabolic syndrome.We used an
analysis of covariance (ANCOVA) for the primary endpoint
and for secondary endpoints waist circumference, blood
pressure, and patient-reported outcome scores; this was
supplemented by a repeated measures analysis. The AN-
COVA model included treatment, country, and sex as fixed
effects, and bodyweight at randomisation as covariate. We
aimed to assess whether data provided evidence of superi-
ority of each liraglutide dose to placebo (primary objective)
and to orlistat (secondary objective)’’[176].
ExplanationdData can be analysed in many ways, some
of which may not be strictly appropriate in a particular sit-
uation. It is essential to specify which statistical procedure
was used for each analysis, and further clarification may be
necessary in the results section of the report. The principle
to follow is to, ‘‘Describe statistical methods with enough
detail to enable a knowledgeable reader with access to
the original data to verify the reported results’’ (www.
icmje.org). It is also important to describe details of the
statistical analysis such as intention-to-treat analysis (see
Box 6).
Almost all methods of analysis yield an estimate of the
treatment effect, which is a contrast between the outcomes
in the comparison groups. Authors should accompany this
by a confidence interval for the estimated effect, which in-
dicates a central range of uncertainty for the true treatment
effect. The confidence interval may be interpreted as the
Box 4. Blinding terminology
In order for a technical term to have utility it must have consistency in its use and interpretation. Authors of trials
commonly use the term ‘‘double blind’’ and, less commonly, the terms ‘‘single blind’’or ‘‘triple blind.’’ A problem with
this lexicon is that there is great variability in clinician interpretations and epidemiological textbook definitions of these
terms [169]. Moreover, a study of 200 RCTs reported as double blind found 18 different combinations of groups
actually blinded when the authors of these trials were surveyed, and about one in every five of these
trialsdreported as double blindddid not blind participants, healthcare providers, or data collectors [170].
This research shows that terms are ambiguous and, as such, authors and editors should abandon their use. Authors
should instead explicitly report the blinding status of the people involved for whom blinding may influence the validity
of a trial.
Healthcare providers include all personnel (for example, physicians, chiropractors, physiotherapists, nurses) who
care for the participants during the trial. Data collectors are the individuals who collect data on the trial outcomes. Out-
come adjudicators are the individuals who determine whether a participant did experience the outcomes of interest.
Some researchers have also advocated blinding and reporting the blinding status of the data monitoring committee
and the manuscript writers [160]. Blinding of these groups is uncommon, and the value of blinding them is debated
[171].
Sometimes one group of individuals (such as the healthcare providers) are the same individuals fulfilling another role
in a trial (such as data collectors). Even if this is the case, the authors should explicitly state the blinding status of these
groups to allow readers to judge the validity of the trial.
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range of values for the treatment effect that is compatible
with the observed data. It is customary to present a 95%
confidence interval, which gives the range expected to in-
clude the true value in 95 of 100 similar studies.
Study findings can also be assessed in terms of their sta-
tistical significance. The P value represents the probability
that the observed data (or a more extreme result) could have
arisen by chance when the interventions did not truly differ.
Actual P values (for example, P50.003) are strongly pref-
erable to imprecise threshold reports such as P!0.05
[48,177].
Standard methods of analysis assume that the data are
‘‘independent.’’ For controlled trials, this usually means
that there is one observation per participant. Treating mul-
tiple observations from one participant as independent data
is a serious error; such data are produced when outcomes
can be measured on different parts of the body, as in den-
tistry or rheumatology. Data analysis should be based on
counting each participant once [178,179] or should be done
by using more complex statistical procedures [180]. Incor-
rect analysis of multiple observations per individual was
seen in 123 (63%) of 196 trials in rheumatoid arthritis
[108].
5.3.17. Item 12b. Methods for additional analyses, such
as subgroup analyses and adjusted analyses
Examplesd‘‘Proportions of patients responding were
compared between treatment groups with the Mantel-
Haenszel c2 test, adjusted for the stratification variable,
methotrexate use’’[103].
‘‘Pre-specified subgroup analyses according to antioxi-
dant treatment assignment(s), presence or absence of prior
CVD, dietary folic acid intake, smoking, diabetes, aspirin,
hormone therapy, and multivitamin use were performed us-
ing stratified Cox proportional hazards models. These anal-
yses used baseline exposure assessments and were
restricted to participants with nonmissing subgroup data
at baseline’’[181].
ExplanationdAs is the case for primary analyses, the
method of subgroup analysis should be clearly specified.
The strongest analyses are those that look for evidence of
a difference in treatment effect in complementary sub-
groups (for example, older and younger participants),
a comparison known as a test of interaction [182,183]. A
common but misleading approach is to compare P values
for separate analyses of the treatment effect in each group.
It is incorrect to infer a subgroup effect (interaction) from
one significant and one non-significant P value [184]. Such
inferences have a high false positive rate.
Because of the high risk for spurious findings, subgroup
analyses are often discouraged [14,185]. Post hoc subgroup
comparisons (analyses done after looking at the data) are
especially likely not to be confirmed by further studies.
Such analyses do not have great credibility.
In some studies, imbalances in participant characteristics
are adjusted for by using some form of multiple regression
analysis. Although the need for adjustment is much less in
RCTs than in epidemiological studies, an adjusted analysis
may be sensible, especially if one or more variables is
thought to be prognostic [186]. Ideally, adjusted analyses
should be specified in the study protocol (see item 24).
For example, adjustment is often recommended for any
stratification variables (see item 8b) on the principle that
the analysis strategy should follow the design. In RCTs,
the decision to adjust should not be determined by whether
baseline differences are statistically significant (see item
16) [183,187]. The rationale for any adjusted analyses
and the statistical methods used should be specified.
Authors should clarify the choice of variables that were
adjusted for, indicate how continuous variables were han-
dled, and specify whether the analysis was planned or sug-
gested by the data [188]. Reviews of published studies
show that reporting of adjusted analyses is inadequate with
regard to all of these aspects [188e191].
5.4. Results
5.4.1. Item 13. Participant flow (a diagram is strongly
recommended)
5.4.1.1. Item 13a. For each group, the numbers of partici-
pants who were randomly assigned, received intended
treatment, and were analysed for the primary outcome.
ExamplesdSee Figs 2 and 3.
ExplanationdThe design and conduct of some RCTs is
straightforward, and the flow of participants, particularly
were there are no losses to follow-up or exclusions, through
each phase of the study can be described adequately in
a few sentences. In more complex studies, it may be diffi-
cult for readers to discern whether and why some partici-
pants did not receive the treatment as allocated, were lost
to follow-up, or were excluded from the analysis [51]. This
information is crucial for several reasons. Participants who
were excluded after allocation are unlikely to be represen-
tative of all participants in the study. For example, patients
may not be available for follow-up evaluation because they
experienced an acute exacerbation of their illness or harms
of treatment [22,192].
Attrition as a result of loss to follow up, which is often
unavoidable, needs to be distinguished from investigator-
determined exclusion for such reasons as ineligibility,
withdrawal from treatment, and poor adherence to the trial
protocol. Erroneous conclusions can be reached if partici-
pants are excluded from analysis, and imbalances in such
omissions between groups may be especially indicative of
bias [192e194]. Information about whether the investiga-
tors included in the analysis all participants who underwent
randomisation, in the groups to which they were originally
allocated (intention-to-treat analysis (see item 16 and Box
6)), is therefore of particular importance. Knowing the
number of participants who did not receive the intervention
as allocated or did not complete treatment permits the
reader to assess to what extent the estimated efficacy of
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therapy might be underestimated in comparison with ideal
circumstances.
If available, the number of people assessed for eligibility
should also be reported. Although this number is relevant to
external validity only and is arguably less important than
the other counts [195], it is a useful indicator of whether
trial participants were likely to be representative of all eli-
gible participants.
A review of RCTs published in five leading general and
internal medicine journals in 1998 found that reporting of
the flow of participants was often incomplete, particularly
with regard to the number of participants receiving the al-
located intervention and the number lost to follow-up
[51]. Even information as basic as the number of partici-
pants who underwent randomisation and the number
excluded from analyses was not available in up to 20% of
articles [51]. Reporting was considerably more thorough
in articles that included a diagram of the flow of partici-
pants through a trial, as recommended by CONSORT. This
study informed the design of the revised flow diagram in
the revised CONSORT statement [52e54]. The suggested
template is shown in Fig 1, and the counts required are de-
scribed in detail in Table 3.
Some information, such as the number of individuals as-
sessed for eligibility, may not always be known [14], and,
depending on the nature of a trial, some counts may be
more relevant than others. It will sometimes be useful or
necessary to adapt the structure of the flow diagram to a par-
ticular trial. In some situations, other information may use-
fully be added. For example, the flow diagram of a parallel
1905 Patients were assessed  
for eligibility 
509 Were assigned to fractional flow 
reserve guided PCI 
8 Were lost to follow-up 
495 Were assigned to angiography-
guided PCI 
11 Were lost to follow-up 
509 Were included in intention-to-
treat analysis 
496 Were included in intention-to-
treat analysis 
1005 Underwent randomization 
909 Were not eligible 
157 Had left main artery stenosis 
217 Had extreme vessel tortuosity 
or calcification 
105 Did not provide consent 
86 Had contraindication for drug-
eluting stent 
94 Were participating in another 
study 
210 Had logistic reasons 
31 Had other reasons 
Fig. 2. Flow diagram of a multicentre trial of fractional flow reserve versus angiography for guiding percutaneous coronary intervention (PCI) (adapted from
Tonino et al [313]). The diagram includes detailed information on the excluded participants.
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group trial of minimal surgery compared with medical
management for chronic gastro-oesophageal reflux also
included a parallel non-randomised preference group (see
Fig 3) [196].
The exact form and content of the flow diagram may be
varied according to specific features of a trial. For example,
many trials of surgery or vaccination do not include the
possibility of discontinuation. Although CONSORT
strongly recommends using this graphical device to com-
municate participant flow throughout the study, there is
no specific, prescribed format.
5.4.1.2. Item 13b. For each group, losses and exclusions
after randomisation, together with reasons.
Examplesd‘‘There was only one protocol deviation, in
a woman in the study group. She had an abnormal pelvic
measurement and was scheduled for elective caesarean sec-
tion. However, the attending obstetrician judged a trial of
labour acceptable; caesarean section was done when there
was no progress in the first stage of labour’’[197].
‘‘The monitoring led to withdrawal of nine centres, in
which existence of some patients could not be proved, or
other serious violations of good clinical practice had
occurred’’[198].
ExplanationdSome protocol deviations may be re-
ported in the flow diagram (see item 13a)dfor example,
participants who did not receive the intended intervention.
If participants were excluded after randomisation (contrary
to the intention-to-treat principle) because they were found
not to meet eligibility criteria (see item 16), they should be
included in the flow diagram. Use of the term ‘‘protocol de-
viation’’ in published articles is not sufficient to justify
exclusion of participants after randomisation. The nature
of the protocol deviation and the exact reason for excluding
participants after randomisation should always be reported.
5.4.2. Item 14a. Dates defining the periods of recruit-
ment and follow-up
Exampled‘‘Age-eligible participants were recruited .
from February 1993 to September 1994 . Participants
attended clinic visits at the time of randomisation (baseline)
and at 6-month intervals for 3 years’’[199].
ExplanationdKnowing when a study took place and
over what period participants were recruited places the
study in historical context. Medical and surgical therapies,
including concurrent therapies, evolve continuously and
may affect the routine care given to participants during
a trial. Knowing the rate at which participants were re-
cruited may also be useful, especially to other investigators.
The length of follow-up is not always a fixed period after
randomisation. In many RCTs in which the outcome is time
to an event, follow-up of all participants is ended on a spe-
cific date. This date should be given, and it is also useful to
report the minimum, maximum, and median duration of
follow-up [200,201].
A review of reports in oncology journals that used sur-
vival analysis, most of which were not RCTs [201], found
that nearly 80% (104 of 132 reports) included the starting
Assessed for eligibility (n=1078) 
Allocated to surgery (n=178) 
Withdrawn before surgery (n=20) 
Received surgery (n=111) 
Declined surgery (n=47) 
Patients randomised (n=357) 
Ineligible (n=200) 
Eligible but not recruited (n=68) 
Patients in preference study (n=453) 
Baseline questionnaire returned 
(n=175) 
Follow-up time equivalent to 1 year 
after surgery (n=154) 
Withdrawn/lost to follow-up (n=14) 
Response (n=154) 
Non-response (n=10) 
Analysed with Reflux QoL Score 
(n=145) 
Allocated to medicine (n=179) 
Received surgery (n=10) 
Baseline questionnaire returned 
(n=256)
Follow-up time equivalent to 1 year 
after surgery (n=164) 
Withdrawn/lost to follow-up (n=5) 
Death (n=1) 
Response (n=164) 
Non-response (n=9) 
Analysed with Reflux QoL Score 
(n=154) 
Baseline questionnaire returned 
(n=174) 
Baseline questionnaire returned 
(n=189) 
Preference surgery (n=261) 
Withdrawn before surgery (n=16) 
Received surgery (n=218) 
Declined surgery (n=25) 
Surgery referred (n=2) 
Preference medicine (n=192) 
Received surgery (n=3) 
Follow-up time equivalent to 1 year 
after surgery (n=230) 
Withdrawn/lost to follow-up (n=12) 
Death (n=2) 
Response (n=230) 
Non-response (n=17) 
Analysed with Reflux QoL Score 
(n=212)
Follow-up time equivalent to 1 year 
after surgery (n=177) 
Withdrawn/lost to follow-up (n=8) 
Response (n=177) 
Non-response (n=7) 
Analysed with Reflux QoL Score 
(n=163) 
Fig. 3. Flow diagram of minimal surgery compared with medical management for chronic gastro-oesophageal reflux disease (adapted from Grant et al [196]).
The diagram shows a multicentre trial with a parallel non-randomised preference group.
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and ending dates for accrual of patients, but only 24% (32
of 132 reports) also reported the date on which follow-up
ended.
5.4.3. Item 14b. Why the trial ended or was stopped
Examplesd‘‘At the time of the interim analysis, the
total follow-up included an estimated 63% of the total num-
ber of patient-years that would have been collected at the
end of the study, leading to a threshold value of 0.0095,
as determined by the Lan-DeMets alpha-spending function
method . At the interim analysis, the RR was 0.37 in the
intervention group, as compared with the control group,
with a p value of 0.00073, below the threshold value. The
Data and Safety Monitoring Board advised the investigators
to interrupt the trial and offer circumcision to the control
group, who were then asked to come to the investigation
centre, where MC (medical circumcision) was advised
and proposed . Because the study was interrupted, some
participants did not have a full follow-up on that date,
and their visits that were not yet completed are described
as ‘‘planned’’ in this article’’[202].
‘‘In January 2000, problems with vaccine supply neces-
sitated the temporary nationwide replacement of the whole
cell component of the combined DPT/Hib vaccine with
acellular pertussis vaccine. As this vaccine has a different
local reactogenicity profile, we decided to stop the trial
early’’[203].
ExplanationdArguably, trialists who arbitrarily conduct
unplanned interim analyses after very few events accrue us-
ing no statistical guidelines run a high risk of ‘‘catching’’
the data at a random extreme, which likely represents
a large overestimate of treatment benefit [204].
Readers will likely draw weaker inferences from a trial
that was truncated in a data-driven manner versus one that
reports its findings after reaching a goal independent of re-
sults. Thus, RCTs should indicate why the trial came to an
end (see Box 5). The report should also disclose factors
extrinsic to the trial that affected the decision to stop the
trial, and who made the decision to stop the trial, including
reporting the role the funding agency played in the deliber-
ations and in the decision to stop the trial [134].
A systematic review of 143 RCTs stopped earlier than
planned for benefit found that these trials reported stop-
ping after accruing a median of 66 events, estimated a me-
dian relative risk of 0.47 and a strong relation between
the number of events accrued and the size of the effect,
with smaller trials with fewer events yielding the largest
treatment effects (odds ratio 31, 95% confidence interval
12 to 82) [134]. While an increasing number of trials
published in high impact medical journals report stopping
early, only 0.1% of trials reported stopping early for ben-
efit, which contrasts with estimates arising from simula-
tion studies [205] and surveys of data safety and
monitoring committees [206]. Thus, many trials accruing
Table 3
Information required to document the flow of participants through each stage of a randomised trial
Stage Number of people included
Number of people not
included or excluded Rationale
Enrolment People evaluated for potential
enrolment
People who did not meet the
inclusion criteria or met the
inclusion criteria but declined to
be enrolled
These counts indicate whether trial
participants were likely to be
representative of all patients
seen; they are relevant to
assessment of external validity
only, and they are often not
available.
Randomisation Participants randomly assigned Crucial count for defining trial size
and assessing whether a trial has
been analysed by intention to
treat
Treatment allocation Participants who completed
treatment as allocated,
by study group
Participants who did not
complete treatment as
allocated, by study group
Important counts for assessment of
internal validity and
interpretation of results; reasons
for not receiving treatment as
allocated should be given.
Follow-up Participants who completed
treatment as allocated,
by study group
Participants who did not
complete treatment as
allocated, by study group
Important counts for assessment of
internal validity and
interpretation of results; reasons
for not completing treatment or
follow-up should be given.
Participants who completed
follow-up as planned,
by study group
Participants who did not
complete follow-up as
planned, by study group
Analysis Participants included in main
analysis, by study group
Participants excluded from main
analysis, by study group
Crucial count for assessing
whether a trial has been
analysed by intention to treat;
reasons for excluding
participants should be given.
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few participants and reporting large treatment effects may
have been stopped earlier than planned but failed to re-
port this action.
5.4.4. Item 15. A table showing baseline demographic
and clinical characteristics for each group
ExampledSee Table 4
ExplanationdAlthough the eligibility criteria (see item
4a) indicate who was eligible for the trial, it is also impor-
tant to know the characteristics of the participants who
were actually included. This information allows readers, es-
pecially clinicians, to judge how relevant the results of
a trial might be to an individual patient.
Randomised trials aim to compare groups of participants
that differ only with respect to the intervention (treatment).
Although proper random assignment prevents selection
bias, it does not guarantee that the groups are equivalent
at baseline. Any differences in baseline characteristics
are, however, the result of chance rather than bias [32].
The study groups should be compared at baseline for im-
portant demographic and clinical characteristics so that
readers can assess how similar they were. Baseline data
are especially valuable for outcomes that can also be mea-
sured at the start of the trial (such as blood pressure).
Baseline information is most efficiently presented in a ta-
ble (see Table 4). For continuous variables, such as weight
or blood pressure, the variability of the data should be re-
ported, along with average values. Continuous variables
can be summarised for each group by the mean and stan-
dard deviation. When continuous data have an asymmetri-
cal distribution, a preferable approach may be to quote
the median and a centile range (such as the 25th and 75th
centiles) [177]. Standard errors and confidence intervals
are not appropriate for describing variabilitydthey are in-
ferential rather than descriptive statistics. Variables with
a small number of ordered categories (such as stages of dis-
ease I to IV) should not be treated as continuous variables;
instead, numbers and proportions should be reported for
each category [48,177].
Unfortunately significance tests of baseline differences
are still common [23,32,210]; they were reported in half
of 50 RCTs trials published in leading general journals in
1997 [183]. Such significance tests assess the probability
that observed baseline differences could have occurred by
chance; however, we already know that any differences
are caused by chance. Tests of baseline differences are
not necessarily wrong, just illogical [211]. Such hypothesis
testing is superfluous and can mislead investigators and
their readers. Rather, comparisons at baseline should be
based on consideration of the prognostic strength of the var-
iables measured and the size of any chance imbalances that
have occurred [211].
Box 5. Early stopping
RCTs can end when they reach their sample size goal, their event count goal, their length of follow-up goal, or when
they reach their scheduled date of closure. In these situations the trial will stop in a manner independent of its results,
and stopping is unlikely to introduce bias in the results. Alternatively, RCTs can stop earlier than planned because of
the result of an interim analysis showing larger than expected benefit or harm on the experimental intervention. Also
RCTs can stop earlier than planned when investigators find evidence of no important difference between experimental
and control interventions (that is, stopping for futility). In addition, trials may stop early because the trial becomes un-
viable: funding vanishes, researchers cannot access eligible patients or study interventions, or the results of other stud-
ies make the research question irrelevant.
Full reporting of why a trial ended is important for evidence based decision making (see item 14b). Researchers
examining why 143 trials stopped early for benefit found that many failed to report key methodological information
regarding how the decision to stop was reacheddthe planned sample size (n528), interim analysis after which the
trial was stopped (n545), or whether a stopping rule informed the decision (n548) [134]. Item 7b of the checklist
requires the reporting of timing of interim analyses, what triggered them, how many took place, whether these were
planned or ad hoc, and whether there were statistical guidelines and stopping rules in place a priori. Furthermore, it
is helpful to know whether an independent data monitoring committee participated in the analyses (and who
composed it, with particular attention to the role of the funding source) and who made the decision to stop. Often
the data safety and monitoring committee makes recommendations and the funders (sponsors) or the investigators
make the decision to stop.
Trials that stop early for reasons apparently independent of trial findings, and trials that reach their planned termi-
nation, are unlikely to introduce bias by stopping [207]. In these cases, the authors should report whether interim
analyses took place and whether these results were available to the funder.
The push for trials that change the intervention in response to interim results, thus enabling a faster evaluation of
promising interventions for rapidly evolving and fatal conditions, will require even more careful reporting of the pro-
cess and decision to stop trials early [208].
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5.4.5. Item 16. For each group, number of participants
(denominator) included in each analysis and whether
the analysis was by original assigned groups
Examplesd‘‘The primary analysis was intention-to-
treat and involved all patients who were randomly
assigned’’[212].
‘‘One patient in the alendronate group was lost to follow
up; thus data from 31 patients were available for the
intention-to-treat analysis. Five patients were considered
protocol violators . consequently 26 patients remained
for the per-protocol analyses’’[213].
ExplanationdThe number of participants in each group
is an essential element of the analyses. Although the flow
diagram (see item 13a) may indicate the numbers of
participants analysed, these numbers often vary for differ-
ent outcome measures. The number of participants per
group should be given for all analyses. For binary
outcomes, (such as risk ratio and risk difference) the
denominators or event rates should also be reported.
Expressing results as fractions also aids the reader in
assessing whether some of the randomly assigned partici-
pants were excluded from the analysis. It follows that
results should not be presented solely as summary mea-
sures, such as relative risks.
Participants may sometimes not receive the full
intervention, or some ineligible patients may have been
randomly allocated in error. One widely recommended
way to handle such issues is to analyse all participants
according to their original group assignment, regardless
of what subsequently occurred (see Box 6). This ‘‘inten-
tion-to-treat’’ strategy is not always straightforward to im-
plement. It is common for some patients not to complete
a studydthey may drop out or be withdrawn from active
treatmentdand thus are not assessed at the end. If the out-
come is mortality, such patients may be included in the
analysis based on register information, whereas imputation
techniques may need to be used if other outcome data are
missing. The term ‘‘intention-to-treat analysis’’ is often in-
appropriately useddfor example, when those who did not
receive the first dose of a trial drug are excluded from the
analyses [18].
Conversely, analysis can be restricted to only partici-
pants who fulfil the protocol in terms of eligibility, inter-
ventions, and outcome assessment. This analysis is known
as an ‘‘on-treatment’’ or ‘‘per protocol’’ analysis. Exclud-
ing participants from the analysis can lead to erroneous
conclusions. For example, in a trial that compared medical
with surgical therapy for carotid stenosis, analysis limited
to participants who were available for follow-up showed
that surgery reduced the risk for transient ischaemic attack,
stroke, and death. However, intention-to-treat analysis
based on all participants as originally assigned did not show
a superior effect of surgery [214].
Intention-to-treat analysis is generally favoured because
it avoids bias associated with non-random loss of partici-
pants [215e217]. Regardless of whether authors use the
term ‘‘intention-to-treat,’’ they should make clear
which and how many participants are included in each
analysis (see item 13). Non-compliance with assigned
therapy may mean that the intention-to-treat analysis
underestimates the potential benefit of the treatment, and
additional analyses, such as a per protocol analysis, may
therefore be considered [218,219]. It should be noted,
however, that such analyses are often considerably flawed
[220].
In a review of 403 RCTs published in 10 leading medi-
cal journals in 2002, 249 (62%) reported the use of
intention-to-treat analysis for their primary analysis. This
proportion was higher for journals adhering to the
CONSORT statement (70% v 48%). Among articles that
reported the use of intention-to-treat analysis, only 39%
actually analysed all participants as randomised, with more
than 60% of articles having missing data in their primary
analysis [221]. Other studies show similar findings
[18,222,223]. Trials with no reported exclusions are meth-
odologically weaker in other respects than those that report
on some excluded participants [173], strongly indicating
that at least some researchers who have excluded partici-
pants do not report it. Another study found that reporting
an intention-to-treat analysis was associated with other as-
pects of good study design and reporting, such as describ-
ing a sample size calculation [224].
Table 4
Example of reporting baseline demographic and clinical
characteristics*
Telmisartan (N52954) Placebo (N52972)
Age (years) 66.9 (7.3) 66.9 (7.4)
Sex (female) 1280 (43.3%) 1267 (42.6%)
Smoking status:
Current 293 (9.9%) 289 (9.7%)
Past 1273 (43.1%) 1283 (43.2%)
Ethnic origin:
Asian 637 (21.6%) 624 (21.0%)
Arab 37 (1.3%) 40 (1.3%)
African 51 (1.7%) 55 (1.9%)
European 1801 (61.0%) 1820 (61.2%)
Native or Aboriginal 390 (13.2%) 393 (13.2%)
Other 38 (1.3%) 40 (1.3%)
Blood pressure
(mm Hg)
140.7 (16.8/81.8)
(10.1)
141.3 (16.4/82.0)
(10.2)
Heart rate
(beats per min)
68.8 (11.5) 68.8 (12.1)
Cholesterol (mmol/l):
Total 5.09 (1.18) 5.08 (1.15)
LDL 3.02 (1.01) 3.03 (1.02)
HDL 1.27 (0.37) 1.28 (0.41)
Coronary artery disease 2211 (74.8%) 2207 (74.3%)
Myocardial infarction 1381 (46.8%) 1360 (45.8%)
Angina pectoris 1412 (47.8%) 1412 (47.5%)
Peripheral artery disease 349 (11.8%) 323 (10.9%)
Hypertension 2259 (76.5%) 2269 (76.3%)
Diabetes 1059 (35.8%) 1059 (35.6%)
* Data are means (SD) or numbers (%).
Adapted from Table 1 of Yusuf et al [209].
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5.4.6. Item 17a. For each primary and secondary out-
come, results for each group, and the estimated effect
size and its precision (such as 95% confidence interval)
ExamplesdSee Tables 5 and 6.
ExplanationdFor each outcome, study results should
be reported as a summary of the outcome in each group
(for example, the number of participants with or without
the event and the denominators, or the mean and stan-
dard deviation of measurements), together with the con-
trast between the groups, known as the effect size. For
binary outcomes, the effect size could be the risk ratio
(relative risk), odds ratio, or risk difference; for survival
time data, it could be the hazard ratio or difference in
median survival time; and for continuous data, it is
Box 6. Intention-to-treat analysis
The special strength of the RCT is the avoidance of bias when allocating interventions to trial participants (see Box
1). That strength allows strong inferences about cause and effect that are not justified with other study designs. In order
to preserve fully the huge benefit of randomisation we should include all randomised participants in the analysis, all
retained in the group to which they were allocated. Those two conditions define an ‘‘intention-to-treat’’ analysis,
which is widely recommended as the preferred analysis strategy [18,223]. Intention-to-treat analysis corresponds to
analysing the groups exactly as randomised. Strict intention-to-treat analysis is often hard to achieve for two main rea-
sonsdmissing outcomes for some participants and non-adherence to the trial protocol.
Missing outcomes
Many trialists exclude patients without an observed outcome. Often this is reasonable, but once any randomised par-
ticipants are excluded the analysis is not strictly an intention-to-treat analysis. Indeed, most randomised trials have
some missing observations. Trialists effectively must choose between omitting the participants without final outcome
data or imputing their missing outcome data [225]. A ‘‘complete case’’ (or ‘‘available case’’) analysis includes only
those whose outcome is known. While a few missing outcomes will not cause a problem, in half of trials more than
10% of randomised patients may have missing outcomes [226]. This common approach will lose power by reducing
the sample size, and bias may well be introduced if being lost to follow-up is related to a patient’s response to treat-
ment. There should be concern when the frequency or the causes of dropping out differ between the intervention
groups.
Participants with missing outcomes can be included in the analysis only if their outcomes are imputed (that is, their
outcomes are estimated from other information that was collected). Imputation of the missing data allows the analysis
to conform to intention-to-treat analysis but requires strong assumptions, which may be hard to justify [227]. Simple
imputation methods are appealing, but their use may be inadvisable. In particular, a widely used method is ‘‘last
observation carried forward’’ in which missing final values of the outcome variable are replaced by the last known
value before the participant was lost to follow up. This is appealing through its simplicity, but the method may
introduce bias [228], and no allowance is made for the uncertainty of imputation [229]. Many authors have severely
criticised last observation carried forward [229e231].
Non-adherence to the protocol
A separate issue is that the trial protocol may not have been followed fully for some trial participants. Common exam-
ples are participants who did not meet the inclusion criteria (such as wrong diagnosis, too young), received a proscribed
co-intervention, did not take all the intended treatment, or received a different treatment or no intervention. The simple
way to deal with any protocol deviations is to ignore them: all participants can be included in the analysis regardless of
adherence to the protocol, and this is the intention-to-treat approach. Thus, exclusion of any participants for such rea-
sons is incompatible with intention-to-treat analysis.
The term ‘‘modified intention-to-treat’’ is quite widely used to describe an analysis that excludes participants who did
not adequately adhere to the protocol, in particular those who did not receive a defined minimum amount of the inter-
vention [232]. An alternative term is ‘‘per protocol.’’ Though a per protocol analysis may be appropriate in some
settings, it should be properly labelled as a non-randomised, observational comparison. Any exclusion of patients from
the analysis compromises the randomisation and may lead to bias in the results.
Like ‘‘intention-to-treat,’’ none of these other labels reliably clarifies exactly which patients were included. Thus, in the
CONSORT checklist we have dropped the specific request for intention-to-treat analysis in favour of a clear description
of exactly who was included in each analysis.
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usually the difference in means. Confidence intervals
should be presented for the contrast between groups.
A common error is the presentation of separate confi-
dence intervals for the outcome in each group rather
than for the treatment effect [233]. Trial results are of-
ten more clearly displayed in a table rather than in the
text, as shown in Tables 5 and 6.
For all outcomes, authors should provide a confidence
interval to indicate the precision (uncertainty) of the es-
timate [48,235]. A 95% confidence interval is conven-
tional, but occasionally other levels are used. Many
journals require or strongly encourage the use of confi-
dence intervals [236]. They are especially valuable in re-
lation to differences that do not meet conventional
statistical significance, for which they often indicate that
the result does not rule out an important clinical differ-
ence. The use of confidence intervals has increased mark-
edly in recent years, although not in all medical
specialties [233]. Although P values may be provided
in addition to confidence intervals, results should not
be reported solely as P values [237,238]. Results should
be reported for all planned primary and secondary end
points, not just for analyses that were statistically signif-
icant or ‘‘interesting.’’ Selective reporting within a study
is a widespread and serious problem [55,57]. In trials in
which interim analyses were performed, interpretation
should focus on the final results at the close of the trial,
not the interim results [239].
For both binary and survival time data, expressing the
results also as the number needed to treat for benefit or
harm can be helpful (see item 21) [240,241].
5.4.7. Item 17b. For binary outcomes, presentation of
both absolute and relative effect sizes is recommended
Exampled‘‘The risk of oxygen dependence or death
was reduced by 16% (95% CI 25% to 7%). The absolute
difference was 6.3% (95% CI 9.9% to 2.7%); early
administration to an estimated 16 babies would therefore
prevent 1 baby dying or being long-term dependent on ox-
ygen’’ (also see Table 7) [242].
ExplanationdWhen the primary outcome is binary, both
the relative effect (risk ratio (relative risk) or odds ratio)
and the absolute effect (risk difference) should be reported
(with confidence intervals), as neither the relative measure
nor the absolute measure alone gives a complete picture of
the effect and its implications. Different audiences may pre-
fer either relative or absolute risk, but both doctors and lay
people tend to overestimate the effect when it is presented
in terms of relative risk [243e245]. The size of the risk dif-
ference is less generalisable to other populations than the
relative risk since it depends on the baseline risk in the un-
exposed group, which tends to vary across populations. For
diseases where the outcome is common, a relative risk near
unity might indicate clinically important differences in pub-
lic health terms. In contrast, a large relative risk when the
outcome is rare may not be so important for public health
(although it may be important to an individual in a high risk
category).
5.4.8. Item 18. Results of any other analyses performed,
including subgroup analyses and adjusted analyses, dis-
tinguishing pre-specified from exploratory
Exampled‘‘On the basis of a study that suggested peri-
operative b-blocker efficacy might vary across baseline
risk, we prespecified our primary subgroup analysis on
the basis of the revised cardiac risk index scoring system.
We also did prespecified secondary subgroup analyses
based on sex, type of surgery, and use of an epidural or spi-
nal anaesthetic. For all subgroup analyses, we used Cox
proportional hazard models that incorporated tests for
Table 5
Example of reporting of summary results for each study group (binary
outcomes)*
Endpoint
Number (%)
Risk
difference
(95% CI)
Etanercept
(n530)
Placebo
(n530)
Primary endpoint
Achieved PsARC
at 12 weeks
26 (87) 7 (23) 63% (44 to 83)
Secondary endpoint
Proportion of patients
meeting ACR criteria:
ACR20 22 (73) 4 (13) 60% (40 to 80)
ACR50 15 (50) 1 (3) 47% (28 to 66)
ACR70 4 (13) 0 (0) 13% (1 to 26)
PsARC5psoriatic arthritis response criteria. ACR5American College
of Rheumatology.
* See also example for item 6a.
Adapted from table 2 of Mease et al [103].
Table 6
Example of reporting of summary results for each study group (continuous outcomes)
Exercise therapy (n565) Control (n566)
Adjusted difference* (95%
CI) at 12 monthsBaseline (mean (SD)) 12 months (mean (SD)) Baseline (mean (SD)) 12 months (mean (SD))
Function score (0e100) 64.4 (13.9) 83.2 (14.8) 65.9 (15.2) 79.8 (17.5) 4.52 (0.73 to 9.76)
Pain at rest (0e100) 4.14 (2.3) 1.43 (2.2) 4.03 (2.3) 2.61 (2.9) 1.29 (2.16 to 0.42)
Pain on activity (0e100) 6.32 (2.2) 2.57 (2.9) 5.97 (2.3) 3.54 (3.38) 1.19 (2.22 to 0.16)
* Function score adjusted for baseline, age, and duration of symptoms.
Adapted from table 3 of van Linschoten [234].
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interactions, designated to be significant at p!0.05 .
Figure 3 shows the results of our prespecified subgroup
analyses and indicates consistency of effects . Our sub-
group analyses were underpowered to detect the modest
differences in subgroup effects that one might expect to de-
tect if there was a true subgroup effect’’[100].
ExplanationdMultiple analyses of the same data create
a risk for false positive findings [246]. Authors should resist
the temptation to perform many subgroup analyses
[183,185,247]. Analyses that were prespecified in the trial
protocol (see item 24) are much more reliable than those
suggested by the data, and therefore authors should report
which analyses were prespecified. If subgroup analyses
were undertaken, authors should report which subgroups
were examined, why, if they were prespecified, and how
many were prespecified. Selective reporting of subgroup
analyses could lead to bias [248]. When evaluating a sub-
group the question is not whether the subgroup shows a sta-
tistically significant result but whether the subgroup
treatment effects are significantly different from each other.
To determine this, a test of interaction is helpful, although
the power for such tests is typically low. If formal evalua-
tions of interaction are undertaken (see item 12b) they
should be reported as the estimated difference in the inter-
vention effect in each subgroup (with a confidence inter-
val), not just as P values.
In one survey, 35 of 50 trial reports included subgroup
analyses, of which only 42% used tests of interaction
[183]. It was often difficult to determine whether subgroup
analyses had been specified in the protocol. In another
survey of surgical trials published in high impact journals,
27 of 72 trials reported 54 subgroup analyses, of which
91% were post hoc and only 6% of subgroup analyses used
a test of interaction to assess whether a subgroup effect ex-
isted [249].
Similar recommendations apply to analyses in which
adjustment was made for baseline variables. If done, both
unadjusted and adjusted analyses should be reported.
Authors should indicate whether adjusted analyses, includ-
ing the choice of variables to adjust for, were planned.
Ideally, the trial protocol should state whether adjustment
is made for nominated baseline variables by using analysis
of covariance [187]. Adjustment for variables because
they differ significantly at baseline is likely to bias the
estimated treatment effect [187]. A survey found that
unacknowledged discrepancies between protocols and
publications were found for all 25 trials reporting sub-
group analyses and for 23 of 28 trials reporting adjusted
analyses [92].
5.4.9. Item 19. All important harms or unintended
effects in each group
For specific guidance see CONSORT for harms [42].
Exampled‘‘The proportion of patients experiencing any
adverse event was similar between the rBPI21 [recombi-
nant bactericidal/permeability-increasing protein] and
placebo groups: 168 (88.4%) of 190 and 180 (88.7%) of
203, respectively, and it was lower in patients treated with
rBPI21 than in those treated with placebo for 11 of 12 body
systems. the proportion of patients experiencing a severe
adverse event, as judged by the investigators, was numeri-
cally lower in the rBPI21 group than the placebo group: 53
(27.9%) of 190 versus 74 (36.5%) of 203 patients, respec-
tively. There were only three serious adverse events re-
ported as drug-related and they all occurred in the
placebo group’’[250].
ExplanationdReaders need information about the
harms as well as the benefits of interventions to make ratio-
nal and balanced decisions. The existence and nature of ad-
verse effects can have a major impact on whether
a particular intervention will be deemed acceptable and
useful. Not all reported adverse events observed during
a trial are necessarily a consequence of the intervention;
some may be a consequence of the condition being treated.
Randomised trials offer the best approach for providing
safety data as well as efficacy data, although they cannot
detect rare harms.
Many reports of RCTs provide inadequate information
on adverse events. A survey of 192 drug trials published
from 1967 to 1999 showed that only 39% had adequate re-
porting of clinical adverse events and 29% had adequate re-
porting of laboratory defined toxicity [72]. More recently,
a comparison between the adverse event data submitted
to the trials database of the National Cancer Institute, which
sponsored the trials, and the information reported in journal
articles found that low grade adverse events were underre-
ported in journal articles. High grade events (Common
Toxicity Criteria grades 3 to 5) were reported inconsistently
in the articles, and the information regarding attribution to
investigational drugs was incomplete [251]. Moreover,
a review of trials published in six general medical journals
in 2006 to 2007 found that, although 89% of 133 reports
mentioned adverse events, no information on severe
adverse events and withdrawal of patients due to an
adverse event was given on 27% and 48% of articles, re-
spectively [252].
An extension of the CONSORT statement has been de-
veloped to provide detailed recommendations on the report-
ing of harms in randomised trials [42]. Recommendations
and examples of appropriate reporting are freely available
from the CONSORT website (www.consort-statement.
org). They complement the CONSORT 2010 Statement
and should be consulted, particularly if the study of harms
was a key objective. Briefly, if data on adverse events were
collected, events should be listed and defined, with refer-
ence to standardised criteria where appropriate. The
methods used for data collection and attribution of events
should be described. For each study arm the absolute risk
of each adverse event, using appropriate metrics for recur-
rent events, and the number of participants withdrawn due
to harms should be presented. Finally, authors should pro-
vide a balanced discussion of benefits and harms [42].
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5.5. Discussion
5.5.1. Item 20. Trial limitations, addressing sources
of potential bias, imprecision, and, if relevant,
multiplicity of analyses
Exampled‘‘The preponderance of male patients (85%)
is a limitation of our study . We used bare-metal stents,
since drug-eluting stents were not available until late during
accrual. Although the latter factor may be perceived as
a limitation, published data indicate no benefit (either
short-term or long-term) with respect to death and myocar-
dial infarction in patients with stable coronary artery dis-
ease who receive drug-eluting stents, as compared with
those who receive bare-metal stents’’[253].
ExplanationdThe discussion sections of scientific re-
ports are often filled with rhetoric supporting the authors’
findings [254] and provide little measured argument of
the pros and cons of the study and its results. Some journals
have attempted to remedy this problem by encouraging
more structure to authors’ discussion of their results
[255,256]. For example, Annals of Internal Medicine rec-
ommends that authors structure the discussion section by
presenting (1) a brief synopsis of the key findings, (2) con-
sideration of possible mechanisms and explanations, (3)
comparison with relevant findings from other published
studies (whenever possible including a systematic review
combining the results of the current study with the results
of all previous relevant studies), (4) limitations of the pres-
ent study (and methods used to minimise and compensate
for those limitations), and (5) a brief section that summa-
rises the clinical and research implications of the work,
as appropriate [255]. We recommend that authors follow
these sensible suggestions, perhaps also using suitable sub-
headings in the discussion section.
Although discussion of limitations is frequently omitted
from research reports [257], identification and discussion of
the weaknesses of a study have particular importance [258].
For example, a surgical group reported that laparoscopic
cholecystectomy, a technically difficult procedure, had signif-
icantly lower rates of complications than the more traditional
open cholecystectomy for management of acute cholecystitis
[259]. However, the authors failed to discuss an obvious bias
in their results. The study investigators had completed all
the laparoscopic cholecystectomies, whereas 80% of the open
cholecystectomies had been completed by trainees.
Authors should also discuss any imprecision of the re-
sults. Imprecision may arise in connection with several as-
pects of a study, including measurement of a primary
outcome (see item 6a) or diagnosis (see item 4a). Perhaps
the scale used was validated on an adult population but
used in a paediatric one, or the assessor was not trained
in how to administer the instrument.
The difference between statistical significance and clin-
ical importance should always be borne in mind. Authors
should particularly avoid the common error of interpreting
a non-significant result as indicating equivalence of inter-
ventions. The confidence interval (see item 17a) provides
valuable insight into whether the trial result is compatible
with a clinically important effect, regardless of the P value
[120].
Authors should exercise special care when evaluating
the results of trials with multiple comparisons. Such multi-
plicity arises from several interventions, outcome measures,
time points, subgroup analyses, and other factors. In such
circumstances, some statistically significant findings are
likely to result from chance alone.
5.5.2. Item 21. Generalisability (external validity,
applicability) of the trial findings
Examplesd‘‘As the intervention was implemented for
both sexes, all ages, all types of sports, and at different
levels of sports, the results indicate that the entire range
of athletes, from young elite to intermediate and recrea-
tional senior athletes, would benefit from using the pre-
sented training programme for the prevention of
recurrences of ankle sprain. By including non-medically
treated and medically treated athletes, we covered a broad
spectrum of injury severity. This suggests that the present
training programme can be implemented in the treatment
of all athletes. Furthermore, as it is reasonable to assume
that ankle sprains not related to sports are comparable with
those in sports, the programme could benefit the general
population’’[260].
‘‘This replicates and extends the work of Clarke and col-
leagues and demonstrates that this CB (cognitive behaviou-
ral) prevention program can be reliably and effectively
delivered in different settings by clinicians outside of the
group who originally developed the intervention. The effect
size was consistent with those of previously reported,
Table 7
Example of reporting both absolute and relative effect sizes
Primary outcome
Percentage (No)
Risk ratio (95% CI) Risk difference (95% CI)
Early administration
(n51344)
Delayed selective
administration (n51346)
Death or oxygen
dependence at
‘‘expected date
of delivery’’
31.9 (429) 38.2 (514) 0.84 (0.75 to 0.93) 6.3 (9.9 to 2.7)
Adapted from table 3 of The OSIRIS Collaborative Group [242].
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single-site, indicated depression prevention studies and was
robust across sites with respect to both depressive disorders
and symptoms . In this generalisability trial, we chose
a comparison condition that is relevant to public healthdu-
sual care . The sample also was predominantly working
class to middle class with access to health insurance. Given
evidence that CB therapy can be more efficacious for ado-
lescents from homes with higher incomes, it will be impor-
tant to test the effects of this prevention program with more
economically and ethnically diverse samples’’[261].
ExplanationdExternal validity, also called generalis-
ability or applicability, is the extent to which the results
of a study can be generalised to other circumstances
[262]. Internal validity, the extent to which the design and
conduct of the trial eliminate the possibility of bias, is a pre-
requisite for external validity: the results of a flawed trial
are invalid and the question of its external validity becomes
irrelevant. There is no absolute external validity; the term is
meaningful only with regard to clearly specified conditions
that were not directly examined in the trial. Can results be
generalised to an individual participant or groups that differ
from those enrolled in the trial with regard to age, sex, se-
verity of disease, and comorbid conditions? Are the results
applicable to other drugs within a class of similar drugs, to
a different dose, timing, and route of administration, and to
different concomitant therapies? Can similar results be ex-
pected at the primary, secondary, and tertiary levels of care?
What about the effect on related outcomes that were not as-
sessed in the trial, and the importance of length of follow-
up and duration of treatment, especially with respect to
harms? [263].
External validity is a matter of judgment and depends on
the characteristics of the participants included in the trial,
the trial setting, the treatment regimens tested, and the out-
comes assessed [5,136]. It is therefore crucial that adequate
information be described about eligibility criteria and the
setting and location (see item 4b), the interventions and
how they were administered (see item 5), the definition of
outcomes (see item 6), and the period of recruitment and
follow-up (see item 14). The proportion of control group
participants in whom the outcome develops (control group
risk) is also important. The proportion of eligible partici-
pants who refuse to enter the trial as indicated on the flow-
chart (see item 13) is relevant for the generalisability of the
trial, as it may indicate preferences for or acceptability of
an intervention. Similar considerations may apply to clini-
cian preferences [264,265].
Several issues are important when results of a trial are
applied to an individual patient [266e268]. Although some
variation in treatment response between an individual pa-
tient and the patients in a trial or systematic review is to
be expected, the differences tend to be in magnitude rather
than direction.
Although there are important exceptions [268], therapies
(especially drugs [269]) found to be beneficial in a narrow
range of patients generally have broader application in
actual practice. Frameworks for the evaluation of external
validity have been proposed, including qualitative studies,
such as in integral ‘‘process evaluations’’[270] and check-
lists [271]. Measures that incorporate baseline risk when
calculating therapeutic effects, such as the number needed
to treat to obtain one additional favourable outcome and
the number needed to treat to produce one adverse effect,
are helpful in assessing the benefit-to-risk balance in an in-
dividual patient or group with characteristics that differ
from the typical trial participant [268,272,273]. Finally, af-
ter deriving patient centred estimates for the potential ben-
efit and harm from an intervention, the clinician must
integrate them with the patient’s values and preferences
for therapy. Similar considerations apply when assessing
the generalisability of results to different settings and
interventions.
5.5.3. Item 22. Interpretation consistent with results,
balancing benefits and harms, and considering other rel-
evant evidence
Exampled‘‘Studies published before 1990 suggested
that prophylactic immunotherapy also reduced nosocomial
infections in very-low-birth-weight infants. However, these
studies enrolled small numbers of patients; employed var-
ied designs, preparations, and doses; and included diverse
study populations. In this large multicenter, randomised
controlled trial, the repeated prophylactic administration
of intravenous immune globulin failed to reduce the inci-
dence of nosocomial infections significantly in premature
infants weighing 501 to 1500 g at birth’’[274].
ExplanationdReaders will want to know how the
present trial’s results relate to those of other RCTs. This
can best be achieved by including a formal systematic re-
view in the results or discussion section of the report
[83,275e277]. Such synthesis may be impractical for trial
authors, but it is often possible to quote a systematic review
of similar trials. A systematic review may help readers as-
sess whether the results of the RCT are similar to those of
other trials in the same topic area and whether participants
are similar across studies. Reports of RCTs have often not
dealt adequately with these points [277]. Bayesian methods
can be used to statistically combine the trial data with pre-
vious evidence [278].
We recommend that, at a minimum, the discussion
should be as systematic as possible and be based on a com-
prehensive search, rather than being limited to studies that
support the results of the current trial [279].
5.6. Other information
5.6.1. Item 23. Registration number and name of trial
registry
Exampled‘‘The trial is registered at ClinicalTrials.gov,
number NCT00244842’’[280].
ExplanationdThe consequences of non-publication of
entire trials [281,282], selective reporting of outcomes
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within trials, and of per protocol rather than intention-to-
treat analysis have been well documented [55,56,283]. Co-
vert redundant publication of clinical trials can also cause
problems, particularly for authors of systematic reviews
when results from the same trial are inadvertently included
more than once [284].
To minimise or avoid these problems there have been re-
peated calls over the past 25 years to register clinical trials
at their inception, to assign unique trial identification num-
bers, and to record other basic information about the trial so
that essential details are made publicly available
[285e288]. Provoked by recent serious problems of with-
holding data [289], there has been a renewed effort to reg-
ister randomised trials. Indeed, the World Health
Organisation states that ‘‘the registration of all intervention-
al trials is a scientific, ethical and moral responsibility’’
(www.who.int/ictrp/en). By registering a randomised trial,
authors typically report a minimal set of information and
obtain a unique trial registration number.
In September 2004 the International Committee of Med-
ical Journal Editors (ICMJE) changed their policy, saying
that they would consider trials for publication only if they
had been registered before the enrolment of the first partic-
ipant [290]. This resulted in a dramatic increase in the num-
ber of trials being registered [291]. The ICMJE gives
guidance on acceptable registries (www.icmje.org/faq.pdf).
In a recent survey of 165 high impact factor medical
journals’ instructions to authors, 44 journals specifically
stated that all recent clinical trials must be registered as a re-
quirement of submission to that journal [292].
Authors should provide the name of the register and the
trial’s unique registration number. If authors had not regis-
tered their trial they should explicitly state this and give the
reason.
5.6.2. Item 24. Where the full trial protocol can be
accessed, if available
Exampled‘‘Full details of the trial protocol can be
found in the Supplementary Appendix, available with the
full text of this article at www.nejm.org’’[293].
ExplanationdA protocol for the complete trial (rather
than a protocol of a specific procedure within a trial) is im-
portant because it pre-specifies the methods of the rando-
mised trial, such as the primary outcome (see item 6a).
Having a protocol can help to restrict the likelihood of un-
declared post hoc changes to the trial methods and selective
outcome reporting (see item 6b). Elements that may be im-
portant for inclusion in the protocol for a randomised trial
are described elsewhere [294].
There are several options for authors to consider ensur-
ing their trial protocol is accessible to interested readers. As
described in the example above, journals reporting a trial’s
primary results can make the trial protocol available on
their web site. Accessibility to the trial results and protocol
is enhanced when the journal is open access. Some journals
(such as Trials) publish trial protocols, and such
a publication can be referenced when reporting the trial’s
principal results. Trial registration (see item 23) will also
ensure that many trial protocol details are available, as
the minimum trial characteristics included in an approved
trial registration database includes several protocol items
and results (www.who.int/ictrp/en). Trial investigators
may also be able to post their trial protocol on a website
through their employer. Whatever mechanism is used, we
encourage all trial investigators to make their protocol
easily accessible to interested readers.
5.6.3. Item 25. Sources of funding and other support
(such as supply of drugs), role of funders
Examplesd‘‘Grant support was received for the inter-
vention from Plan International and for the research from
the Wellcome Trust and Joint United Nations Programme
on HIV/AIDS (UNAIDS). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript’’[295].
‘‘This study was funded by GlaxoSmithKline Pharma-
ceuticals. GlaxoSmithKline was involved in the design
and conduct of the study and provided logistical support
during the trial. Employees of the sponsor worked with
the investigators to prepare the statistical analysis plan,
but the analyses were performed by the University of Utah.
The manuscript was prepared by Dr Shaddy and the steer-
ing committee members. GlaxoSmithKline was permitted
to review the manuscript and suggest changes, but the final
decision on content was exclusively retained by the
authors’’[296].
ExplanationdAuthors should report the sources of fund-
ing for the trial, as this is important information for readers
assessing a trial. Studies have showed that research
sponsored by the pharmaceutical industry are more likely
to produce results favouring the product made by the
company sponsoring the research than studies funded by
other sources [297e300]. A systematic review of 30 studies
on funding found that research funded by the pharmaceuti-
cal industry had four times the odds of having outcomes
favouring the sponsor than research funded by other
sources (odds ratio 4.05, 95% confidence interval 2.98 to
5.51) [297]. A large proportion of trial publications do
not currently report sources of funding. The degree of
underreporting is difficult to quantify. A survey of 370 drug
trials found that 29% failed to report sources of funding
[301]. In another survey, of PubMed indexed randomised
trials published in December 2000, source of funding was
reported for 66% of the 519 trials [16].
The level of involvement by a funder and their influence
on the design, conduct, analysis, and reporting of a trial
varies. It is therefore important that authors describe in de-
tail the role of the funders. If the funder had no such in-
volvement, the authors should state so. Similarly, authors
should report any other sources of support, such as supply
and preparation of drugs or equipment, or in the analysis of
data and writing of the manuscript [302].
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6. Reporting RCTs that did not have a two group
parallel design
The primary focus of the CONSORT recommendations
is RCTs with a parallel design and two treatment groups.
Most RCTs have that design, but a substantial minority
do not: 45% (233/519) of RCTs published in December
2000 [16], and 39% (242/616) in December 2006 [17].
Most of the CONSORT statement applies equally to all
trial designs, but there are a few additional issues to address
for each design. Before the publication of the revised CON-
SORT statement in 2001, the CONSORT Group decided to
develop extensions to the main CONSORT statement rele-
vant to specific trial designs. Extensions have been published
relating to reporting of cluster randomised trials [40] and
non-inferiority and equivalence trials [39]. Lack of resources
has meant that other planned extensions have not been com-
pleted; they will cover trials with the following designs:
multiarm parallel, factorial, crossover, within-person.
Authors reporting trials with a cluster design or using
a non-inferiority or equivalence framework should consult
the CONSORT recommendations in addition to those in this
document. Here we make a few interim comments about the
other designs. In each case, the trial design should be made
clear in both the main text and the article’s abstract.
Multiarm (O2 group) parallel group trials need the least
modification of the standard CONSORT guidance. The flow
diagram can be extended easily. The main differences from
trials with two groups relate to clarification of how the study
hypotheses relate to the multiple groups, and the consequent
methods of data analysis and interpretation. For factorial tri-
als, the possibility of interaction between the interventions
generally needs to be considered. In addition to overall
comparisons of participants who did or did not receive each
intervention under study, investigators should consider also
reporting results for each treatment combination [303].
In crossover trials, each participant receives two (or
more) treatments in a random order. The main additional is-
sues to address relate to the paired nature of the data, which
affect design and analysis [304]. Similar issues affect
within-person comparisons, in which participants receive
two treatments simultaneously (often to paired organs).
Also, because of the risk of temporal or systemic carryover
effects, respectively, in both cases the choice of design
needs justification.
The CONSORT Group intends to publish extensions to
CONSORT to cover all these designs. In addition, wewill pub-
lish updates to existing guidance for cluster randomised trials
and non-inferiority and equivalence trials to take account of
this major update of the generic CONSORT guidance.
7. Discussion
Assessment of healthcare interventions can be mislead-
ing unless investigators ensure unbiased comparisons. Ran-
dom allocation to study groups remains the only method
that eliminates selection and confounding biases. Non-
randomised trials tend to result in larger estimated treat-
ment effects than randomised trials [305,306].
Bias jeopardises even RCTs, however, if investigators
carry out such trials improperly [307]. A recent systematic
review, aggregating the results of several methodological
investigations, found that, for subjective outcomes, trials
that used inadequate or unclear allocation concealment
yielded 31% larger estimates of effect than those that used
adequate concealment, and trials that were not blinded
yielded 25% larger estimates [153]. As might be expected,
there was a strong association between the two.
The design and implementation of an RCT require
methodological as well as clinical expertise, meticulous
effort [143,308], and a high level of alertness for unantici-
pated difficulties. Reports of RCTs should be written with
similarly close attention to reducing bias. Readers should
not have to speculate; the methods used should be complete
and transparent so that readers can readily differentiate
trials with unbiased results from those with questionable
results. Sound science encompasses adequate reporting,
and the conduct of ethical trials rests on the footing of
sound science [309].
We hope this update of the CONSORT explanatory
article will assist authors in using the 2010 version of
CONSORT and explain in general terms the importance
of adequately reporting of trials. The CONSORT statement
can help researchers designing trials in future [310] and can
guide peer reviewers and editors in their evaluation of man-
uscripts. Indeed, we encourage peer reviewers and editors
to use the CONSORT checklist to assess whether authors
have reported on these items. Such assessments will likely
improve the clarity and transparency of published trials.
Because CONSORT is an evolving document, it requires
a dynamic process of continual assessment, refinement,
and, if necessary, change, which is why we have this update
of the checklist and explanatory article. As new evidence
and critical comments accumulate, we will evaluate the
need for future updates.
The first version of the CONSORT statement, from
1996, seems to have led to improvement in the quality of
reporting of RCTs in the journals that have adopted it
[50e54]. Other groups are using the CONSORT template
to improve the reporting of other research designs, such
as diagnostic tests [311] and observational studies [312].
The CONSORT website (www.consort-statement.org)
has been established to provide educational material and
a repository database of materials relevant to the reporting
of RCTs. The site includes many examples from real trials,
including all of the examples included in this article. We
will continue to add good and bad examples of reporting
to the database, and we invite readers to submit further
suggestions by contacting us through the website. The
CONSORT Group will continue to survey the literature to
find relevant articles that address issues relevant to the re-
porting of RCTs, and we invite authors of any such articles
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to notify us about them. All of this information will be
made accessible through the CONSORT website, which is
updated regularly.
More than 400 leading general and specialty journals
and biomedical editorial groups, including the ICMJE,
World Association of Medical Journal Editors, and the
Council of Science Editors, have given their official support
to CONSORT. We invite other journals concerned about the
quality of reporting of clinical trials to endorse the CON-
SORT statement and contact us through our website to let
us know of their support. The ultimate benefactors of these
collective efforts should be people who, for whatever rea-
son, require intervention from the healthcare community.
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